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*UDYHV¶GLVHDVHDQG*UDYHV¶RSKWKDOPRSDWK\ 
*UDYHV¶ GLVHDVH *' *UDYHV¶ K\SHUWK\URLGLVP LV RQH RI WKH PRVW FRPPRQ
autoimmune disorders and accounts for the majority of cases of hyperthyroidism. 
Hyperthyroidism is a pathological syndrome in which tissue is exposed to excessive 
amounts of thyroid hormone, causing typical symptoms as nervousness or anxiety, 
weight loss, palpitations, heat intolerability and fatigue. Hyperthyroidism in GD is caused 
by specific autoantibodies that stimulate the thyrotropin receptor (TSH-receptor; TSHR), 
thereby mimicking the effect of pituitary thyroid stimulating hormone (TSH) 1.  
*UDYHV¶ RSKWKDOPRSDWK\ *2 DOVR UHIHUUHG WR DV WK\URLG H\H GLVHDVH LV DQ
extra-thyroidal complication that develops in ~25-50% of patients with GD and is 
characterized by inflammation and extensive remodeling of the soft tissues surrounding 
the eyes 2. Most patients exhibit extraocular muscle and adipose/connective tissue 
volume increase, while in some patients either extraocular muscle enlargement or 
adipose/connective tissue expansion may predominate 2. Fibroblast and adipocyte 
numbers are increased in extraocular muscle and adipose/connective tissue from GO 
patients, leading to collagen and glycosaminoglycan accumulation between the muscle 
fibers and within the adipose/connective tissue 3. Clinical symptoms of GO result from 
the increased orbital tissue volume within the non-compliant space-limited bony orbit 
and comprise of upper eyelid retraction, edema, erythema of the periorbital tissues and 
conjunctivae, and proptosis. Keratitis can occur in case of severe and prolonged 
proptosis, while optic neuropathy can result from optic nerve compression 2, 3.  
Early active GO is characterized by infiltration of the extraocular muscles and 
adipose/connective tissue with mononuclear cells, primarily CD4+ T-lymphocytes, some 
CD8+ T-lymphocytes, monocytes, macrophages, B-lymphocytes and plasma cells 2, 4-8. 
Mast cells are more abundant in the late fibrotic disease phase 3, 9, 10. These 
inflammatory cells activate orbital fibroblasts via the secretion of inflammatory mediators 
(e.g. cytokines) or by direct cellular interaction 2. Moreover, orbital fibroblasts in GO may 
be activated by stimulatory autoantibodies directed against the TSHR and the insulin-
like growth factor-1 receptor (IGF-1R) 2, 11. The activated orbital fibroblasts increase 
their proliferative activity, produce inflammatory mediators, differentiate into adipocytes 
and myofibroblasts and produce excess amounts of extracellular matrix (ECM) 
components. Thereby, orbital fibroblasts fulfill central roles in orbital inflammation and 
tissue remodeling in GO. This activation, combined with several unique properties and 
heterogeneity within the orbital fibroblast pool, has led to the concept that orbital 
fibroblasts represent the central cell type in the pathogenesis of GO. Important effector 
functions and characteristics of orbital fibroblasts that contribute to the pathogenesis of 
GO will be further discussed.  
 
9 
Chapter 1Introduction
1
5A_BW Virakul stand.job_Press Sheet Size 17x24 cm
ϵ

ϵ

Orbital fibroblasts contribute to orbital inflammation 
 The inflammatory environment within GO orbital tissue is determined by soluble 
and cellular components and strongly influences orbital fibroblast behaviour. In early 
active GO, T-helper 1 (Th1)-lymphocytes dominate and Th1-like cytokines (including a.o. 
interferon (IFN)-J, interleukin (IL)-2 and tumor necrosis factor (TNF)-D) that facilitate cell 
mediated immunity are abundantly present. Although less evident, Th2-lymphocytes and 
associated cytokines (including IL-4 and IL-10) may dominate the later disease stage 
characterized by tissue remodeling and fibrosis (late GO), fitting the current paradigm 
that Th2-like cytokine responses predominate in chronic inflammation and fibrosis 2, 12-16. 
Other T-helper cell subsets that have been indicated in auto-immune disease and 
fibrosis are Th17 and Th22 17-21. However, so far, involvement of Th17 and Th22 cells in 
GO has not been examined, although an association between specific IL-23 receptor 
polymorphisms and GO was suggested; IL-23 drives Th17 pathogenicity and is a 
primary inducer of IL-22 22. There are however some indications that Th17 and Th22 cells 
are involved in GD as increased frequencies of Th17 and Th22 cells in peripheral blood 
from GD patients have been described, but studies on this are not conclusive 23-25. 
Other inflammatory cell types, including monocytes, macrophages and mast cells also 
contribute to the increased orbital cytokine/growth factor levels in GO 10, 26 although the 
contribution of mast cells and their contents to GO remain poorly studied to date.  
The effects of several cytokines and growth factors elevated in GO orbital tissue 
on orbital fibroblast inflammatory activity have been examined. IFN-J stimulates the 
production of chemokine (C-C motif) ligand (CCL)2, a chemotactic factor for monocytes, 
as well as T-lymphocyte chemoattractants such as chemokine (C-X-C motif) ligand 
(CXCL)9, CXCL10 and CXCL11, which is synergistically enhanced by TNF-D  27-29. 
Cytokines and growth factors such as IL-ȕ71)-D and platelet-derived growth factor 
(PDGF)-AA, PDGF-AB and PDGF-BB also stimulate orbital fibroblasts to produce 
cytokines/chemokines like CCL2, CCL5, CCL7, IL-6, IL-8, and IL-16 that are collectively 
involved in recruitment and activation of monocytes, T-lymphocytes, B-lymphocytes and 
mast cells 10, 27, 30-33. Moreover, IL-ȕ DQG OHXNRUHJXOLQ VWLPXODte prostaglandin E2 
(PGE2) production by orbital fibroblasts 34, 35. PGE2 stimulates B-lymphocyte maturation, 
activates mast cells and induces Th2 skewing, but also stimulates IL-6 production by 
orbital fibroblasts 36-39.         
 Leukocyte infiltration and activation in tissue not only depends on local 
chemokine gradients, but also requires expression of adhesion and co-stimulatory 
molecules on leukocytes, endothelial cells and tissue resident cells. Intercellular 
adhesion molecule (ICAM)-1 expression on orbital fibroblasts is upregulated by IL-1D, 
IL-ȕ,)1-J, TNF-D 40-42. The co-stimulatory molecule CD40, highly expressed by orbital 
fibroblasts from GO patients, is further upregulated by IFN-J stimulation 31. CD40-
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CD154 ligation is involved in physical interactions between orbital fibroblasts and T-
lymphocytes in GO and enhances ICAM-1 expression as well as cytokine and 
prostaglandin production (e.g. CCL2, IL-1D, IL-6, IL-8, PGE2) by orbital fibroblasts 31, 43-
45.  
 Collectively, these data illustrate that orbital fibroblasts, through the production of 
inflammatory molecules, are involved in regulating the orbital inflammatory process in 
GO where they orchestrate leukocyte recruitment and activation. 
 
Orbital fibroblasts contribute to orbital tissue expansion 
Proliferation, extracellular matrix production (especially hyaluronan) and 
differentiation of orbital fibroblasts into adipocytes and myofibroblasts are important 
determinants of orbital tissue volume expansion and fibrosis in GO 2, 3 and will be 
discussed. 
 
Orbital fibroblast proliferation 
Fibroblast proliferation is an important contributor to tissue remodeling and 
fibrotic responses 46. The basal proliferative activity of GO orbital fibroblasts was found 
to be higher than that from normal orbital fibroblasts 47. In addition, cellular interactions 
such as CD40-CD154 ligation between T-lymphocytes and orbital fibroblasts, but also 
various cytokines and growth factors, including IL-4, insulin-like growth factor (IGF)-1, 
PDGF and transforming growth factor (TGF)-ȕPRUHVWURQJO\ LQFUHase the proliferation 
rate of GO orbital fibroblasts than that of control orbital fibroblasts  47, 48. Still, studies on 
this are not always consistent, as it has also been described that PDGF-BB stimulates 
proliferation of GO and control orbital fibroblasts equally and that TGF-ȕKDVQRHIIHFW
on orbital fibroblast proliferation 49. PDGF-BB was found to be a stronger mitogen for 
orbital fibroblasts than PDGF-AB, which in turn is more potent than PDGF-AA 10. The 
picture that emerges is that GO orbital fibroblasts are extremely sensitive to mitogenic 
factors and that exaggerated proliferation by these cells contributes to orbital tissue 
expansion and fibrosis in GO.    
 
Hyaluronan production by orbital fibroblasts 
GO orbital tissue contains increased amounts of non-sulfated 
glycosaminoglycans (especially hyaluronan) as well as collagen, which are produced by 
orbital fibroblasts  3. Hyaluronan is the ECM component mostly contributing to orbital 
  orbit  t is ue  contains increased  amounts of  non - sulfat
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tissue expansion in GO. Hyaluronan is estimated to occupy ~75000 times the volume of 
that of an equivalent weight of collagen, which is mainly related to its massive water 
binding capacity 3. Hyaluronan synthesis is regulated by cell membrane expressed 
hyaluronan synthases (HASs), of which three different isoforms exist, HAS1, HAS2, and 
HAS3 50. Of these, HAS2 is considered to represent the major HAS isoform involved in 
hyaluronan synthesis by orbital fibroblasts in GO 51, 52.       
Inflammatory mediators such as leukoregulin, IL-1, TNF-D, IFN-J, TGF-ȕ,*)-1, 
PDGF, prostaglandins and cellular interactions with immune cells enhance hyaluronan 
production by orbital fibroblasts 10, 42, 49, 51, 53-59. Cytokines may act synergistically on 
hyaluronan production by orbital fibroblasts. For instance IL-4 and IFN-J have been 
described to augment the effect of IL-ȕRQK\DOXURQDQSURGXFWLRQE\RUELWDOILEUREODVWV
34. Still, the contribution of specific cytokines and their interactions with other cytokines 
in the pathogenesis of GO is complex and incompletely understood, as illustrated by the 
divergent effects of IL-4 and IFN-J on IL-ȕ-induced hyaluronan and PGE2 production 
by orbital fibroblasts 34.  
Hyaluronan accumulation depends on the balance between synthesis and 
degradation. Recently orbital fibroblasts were found to produce three different 
hyaluronidase isoforms 60. And although enhanced hyaluronan synthesis rather than 
diminished breakdown appears to be the main mechanism of accumulation in GO 60, the 
interaction between hyaluronan synthesis and degradation in GO orbital tissue is still 
incompletely understood.    
 
Adipogenic and myofibroblastic differentiation potential of orbital fibroblasts is 
distinguished by Thy1 expression 
Functional and phenotypic heterogeneity exists within the orbital fibroblast pool 
with regard to their capacity to differentiate into adipocytes. This is confined to at least 
two different orbital fibroblast subpopulations, Thy1(CD90)+ and Thy1- orbital fibroblasts 
61-63.  
Thy1- orbital fibroblasts exhibit high capacity to differentiate into adipocytes 61, 63-
66. Inflammatory mediators including IL-ȕ ,/-6 and PGD2 enhance adipogenesis by 
orbital fibroblasts 42, 58, 67. Remarkably, Th1 cytokines such as IFN-J and TNF-D inhibit 
adipogenic differentiation by orbital fibroblasts, while IL-1D and IL-4 do not affect these 
processes 42, 67. This is consistent with a role for Th1-related cytokines in the early active 
inflammatory phase of GO, rather than the late tissue remodeling phase of the disease. 
Moreover, physical interaction between orbital fibroblasts and autologous T-
lymphocytes drives adipogenic differentiation of orbital fibroblasts in a prostaglandin 
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dependent manner 68. When cultured under pathological pressure in a three-
dimensional collagen matrix Thy1- orbital fibroblasts differentiate into adipocytes. This 
implies that increased mechanical pressure encountered by orbital fibroblasts within the 
space-limited noncompliant orbit may provide pro-adipogenic signals in GO 69. Cigarette 
smoking is the strongest modifiable risk factor for developing GO and cigarette smoke 
extract promotes adipogenic differentiation by orbital fibroblasts 70, although it is unclear 
how this relates to Thy1 expression.    
PPAR-J is an adipocyte predominant nuclear receptor that functions as 
transcription factor and regulates glucose and lipid homeostasis 71. Activation of PPAR-J 
with rosiglitazone enhances adipogenesis by orbital fibroblasts 65. Thiazolidinediones as 
rosiglitazone or piogliatozone are used as treatment for type-2 diabetes. Remarkably, 
GO patients treated with these drugs for type-2 diabetes may encounter orbital 
deterioration due to PPAR-J activation and adipose tissue expansion 72. On the other 
hand, PPAR-J agonists may inhibit orbital inflammation and hyaluronan accumulation 57, 
73. PPAR-J may thus represent an important regulatory factor in GO and well balanced 
PPAR-J activity may be beneficial in GO 73.                
Thy1+ orbital fibroblasts have low adipocyte differentiation potential but exhibit 
high capacity to differentiate into D-smooth muscle actin expressing myofibroblasts, for 
instance when cultured in the presence of the Th2-related growth factor TGF-ȕ 66, 74. 
Myofibroblasts are the main cell type responsible for contraction and collagen 
accumulation in fibrotic tissue 75. These observations are thus consistent with a role of 
Th2-related cytokines in the tissue remodeling/fibrotic phase of late inactive GO where 
Thy1+ orbital fibroblast derived myofibroblasts contribute to fibrosis of the orbital tissues 
63.  
Remarkably, the majority of the fibroblast pool from the adipose/connective 
orbital tissue consists of Thy1+ fibroblasts, while ~30-40% of the fibroblasts are Thy1-. In 
contrast, fibroblasts from the extra-ocular muscles uniformly express Thy1 63. So far 
there is no clear explanation what controls this heterogeneity. There is, however, 
evidence that supports cross-talk between Thy1+ and Thy1- orbital fibroblast 
populations. Culture medium from Thy1+ orbital fibroblasts was found to inhibit 
adipocytic differentiation by Thy1- orbital fibroblasts, indicating secretion of anti-
adipogenic factors by Thy1+ orbital fibroblasts 74. It has been suggested that the 
autoimmune inflammation in GO disrupts the ability of Thy1- orbital fibroblasts to 
respond appropriately to the anti-adipogenic signal produced by the Thy1+ orbital 
fibroblasts, which facilitates adipogenesis in GO 74. It should however be noted that 
isolation and culture of Thy1+ and Thy1- orbital fibroblast populations can be 
troublesome as both purified Thy1+ and Thy1- orbital fibroblast populations may rapidly 
revert into the original mixed phenotype fibroblast pool 69. Nevertheless, differences in 
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the relative proportion of Thy1+ and Thy1- orbital fibroblast populations between GO 
patients and their degree of exposure to specific stimuli, such as TGF-ȕ PD\ EH
involved in observed differences in adipose tissue and extraocular muscle involvement 
in GO patients 2, 63. 
 
Orbital fibroblasts as target for TSHR and IGF-1R autoantibodies  
TSHR is the autoantigen responsible for hyperthyroidism in GD. The close 
clinical association between GD and eye disease has led to the shared (auto)antigen 
hypothesis, which is supported by the positive correlation between TSHR autoantibody 
titer and activity and severity of GO in GD patients 76-78. In addition, TSHR is expressed 
in orbital tissue, which is even higher in GO orbital tissue. This expression is confined to 
orbital fibroblasts, which seems to be a rather unique feature for orbital fibroblasts, since 
fibroblasts from other anatomical sites mostly do not express TSHR 9, 15, 79-83. The 
differentiation of orbital fibroblasts into adipocytes is associated with increased TSHR 
expression, which is currently considered as  main route of enhanced orbital TSHR 
expression in GO 2, 67, 84. PDGF-AB and PDGF-BB were found to rapidly increase TSHR 
expression on orbital fibroblasts 83, but the relation with adipogenesis is unclear so far. 
In contrast, TGF-ȕ UHGXFHV 76+5 H[SUHVVLRQ ZLWKRXW DIIHFWLQJ DGLSRJHQHVLV 84, 85. 
These data illustrate that the level of in vivo TSHR expression by orbital 
fibroblasts/adipocytes in GO is most likely determined by the interplay between the 
various cytokines/growth factors present within the orbital tissue.  
Although the observations described above favor a role for TSHR stimulatory 
autoantibodies and TSHR in GO pathogenesis only few studies examined the effect of 
TSHR activation on orbital fibroblasts. Activation of orbital fibroblasts by TSH, TSHR 
specific stimulatory antibodies, or GD-IgG induced cAMP signaling, phosphoinositide 3-
kinase (PI3K) signaling and the production of cytokines (e.g. CCL2, CCL5, IL-6, IL-8), 
ICAM-1 and hyaluronan 40, 41, 52, 83, 86-88. Furthermore, TSHR activation acts pro-
adipogenic on orbital fibroblasts 86, 89. Importantly, PDGF-enhanced TSHR  expression 
in orbital fibroblasts was found to augment the capacity of GD-IgG to stimulate cytokine 
and hyaluronan production by orbital fibroblasts  83. This points at a direct link between 
TSHR expression levels in orbital fibroblasts and the pathogenicity of the TSHR 
stimulatory autoantibodies in GO. TSHR expression has also been found in pretibial 
fibroblasts from GD patients where it may thus contribute to pretibial myxedema, 
another (less frequent) extra-thyroidal complication of GD that is also characterized by 
increased hyaluronan deposition 2, 3, 82, 90, 91. 
The IGF-1R is expressed at high level by orbital fibroblasts from GO patients 92. 
Stimulatory autoantibodies against IGF-1R have been suggested to contribute to GO by 
14 
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stimulating the production of the T-lymphocyte chemoattractants IL-16 and CCL5 as 
well as hyaluronan by orbital fibroblasts 92, 93. Adversely, a recent study does not 
support the hypothesis that IGF-1R autoantibodies contribute to GO pathogenesis, as a 
similar prevalence of IGF-1R autoantibody positivity was found in GO patients and 
healthy controls. Moreover, in this study the IGF-1R autoantibodies did not activate IGF-
1R signaling but exerted an inhibitory activity on IGF-1R signaling 94.  Furthermore it 
was found that an IGF-1R blocking antibody inhibits M22 (a monoclonal TSHR 
stimulatory antibody)-induced hyaluronan production by orbital fibroblasts, although this 
may be related to a physical and functional association between TSHR and IGF-1R 95, 
96. Therefore, further studies that examine the significance of IGF-1R autoantibodies 
and the pathogenic role they play in orbital fibroblast activation in GO are still required.            
 
Orbital fibroblasts display unique biological responses 
Depending on the anatomical location fibroblasts display characteristic 
transcriptional patterns, indicating that fibroblasts of different anatomical origin 
represent distinctly differentiated cell types 97. In addition to their unique anatomical 
location, orbital fibroblasts are from neuro-ectodermal origin while most other tissue 
fibroblasts are from mesenchymal origin 98. Moreover, orbital fibroblasts display clear 
morphological differences with fibroblasts from other anatomical regions 99. This 
implicates that orbital fibroblasts likely display characteristic features and several 
studies demonstrated that orbital fibroblasts respond differently to stimulation than 
fibroblasts from other anatomical regions. For instance, activation with IL-ȕ ,)1-J, 
TNF-D, leukoregulin, PDGF-BB, or CD40-CD154 ligation results in significantly higher 
cytokine/chemokine, prostaglandin, plasminogen-activator inhibitor type-1 and 
hyaluronan production by orbital fibroblasts compared to other types of fibroblasts 30, 31, 
33, 43, 51, 55, 100, 101. In contrast, skin fibroblasts have been reported to produce significantly 
more CCL7 upon PDGF-BB stimulation than orbital fibroblasts 33. Moreover, PDGF-AB 
and PDGF-BB enhance TSHR expression on orbital fibroblasts, while they do not in 
skin fibroblasts 83. Also, orbital fibroblasts generally produce higher amounts of 
hyaluronan upon activation than fibroblasts from other anatomical regions 55, 102. Altered 
regulation of cell signaling pathways between orbital fibroblasts and other fibroblasts 
may be involved in these different responses, for instance different regulation of NF-NB 
and TGF-ȕ1 signaling have been proposed in orbital fibroblasts 33, 49.  
Orbital fibroblasts from GO patients have repeatedly been reported to exhibit 
different features compared to orbital fibroblasts from healthy controls. For instance, 
higher expression levels of CD40, Thy1 and IGF-1R have been described on orbital 
fibroblasts from GO patients 31, 92, 103. Moreover, GO orbital fibroblasts have been 
reported to display increased proliferative activity under basal conditions or when 
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stimulated with certain cytokines/growth factors 47. GO orbital fibroblasts also produced 
markedly less IL-1 receptor antagonist (IL-1RA) upon stimulation with various cytokines 
(e.g. IL-1D, IFN-J, TNF-D, TGF-ȕ WKDQ QRUPDO RUELWDO ILEUREODVWV 104, suggestive of 
disturbed anti-inflammatory responses. Finally, GO orbital fibroblasts, unlike control 
orbital fibroblasts, have been found to spontaneously differentiate into adipocytes when 
cultured in a three-dimensional collagen matrix 69.  
Chronic inflammation and fibrosis can lead to the emergence of epigenetically 
altered fibroblasts that display a phenotype with DNA methylation aberrancies and 
increased histone deacetylase activity that promotes inflammation and pathologic tissue 
remodeling 105-108. Although not examined so far, occurrence of epigenetic alterations in 
orbital fibroblasts from GO patients may contribute to observed differences with healthy 
control orbital fibroblasts.  
 
Orbital fibrocyte recruitment contributes to GO 
In tissue repair processes fibroblasts can originate from local proliferation, 
recruitment from surrounding undamaged tissue, or through de-differentation processes 
referred to as epithelial/endothelial mesenchymal transition. Furthermore, at sites of 
tissue inflammation/healing fibroblast-like cells can derive from recruitment and 
differentiation of circulating fibrocytes 109. Fibrocytes are bone-marrow derived 
mesenchymal cells that circulate as peripheral blood mononuclear cells and express 
a.o. CD34, CD45, chemokine receptors such as chemokine (C-C motif) receptor 
(CCR)3, CCR5, CCR7 and chemokine (C-X-C motif) receptor (CXCR)4, as well as 
extracellular matrix molecules like type-I, type-III, type-IV collagen and fibronectin 110. 
Fibrocytes rapidly infiltrate sites of tissue damage where they participate in 
inflammation, healing and tissue remodeling, but they are also involved in fibrosis 110. 
Increased fibrocyte numbers have been detected in the fibrotic tissue as well as 
peripheral blood from patients with fibrotic conditions 109, 110.  
Increased numbers of circulating fibrocytes have been reported in peripheral 
blood from GO patients 111. In GO circulating fibrocytes infiltrate the orbital tissue where 
they differentiate into CD34+ orbital fibroblasts, whereas orbital tissue from healthy 
individuals predominantly contains CD34- orbital fibroblasts 111. Orbital fibroblast 
cultures from GO patients contained fibrocyte resembling cells (CD34 and collagen 
type-I positive) that spontaneously differentiated into adipocytes 111. How this relates to 
the previously noted association between Thy1 negativity and the capacity of orbital 
fibroblasts to differentiate into adipocytes is unclear so far, but it may very well 
contribute to the earlier discussed heterogeneity with regard to adipocyte differentiation 
in orbital fibroblast cultures. 
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The pathways and molecules involved in fibrocyte migration into orbital tissue in 
GO are largely unknown, but increased production of specific chemokines within the 
orbital tissue is most likely involved. A major role has been identified for the 
CXCL12/CXCR4 axis in fibrocyte recruitment into tissue 112. Although to date no data 
are available on CXCL12 production in GO several other chemokines involved in 
fibrocyte recruitment, such as CCL2, CCL5 and CCL7 113 are produced by orbital 
fibroblasts, for instance upon stimulation with IFN-J, IL-ȕ71)-D or PDGF-BB, factors 
that are abundantly present in orbital tissue from GO patients 10, 15, 26, 27, 33. Fibrocytes 
also express the PDGF-5ĮDQG3'*)-5ȕ FKDLQV DQG WKHPDGF-BB/PDGF-R-ȕ D[LV
was recently identified as being critical for fibrocyte migration into fibrotic lungs 114. 
However, whether these or other ways of orbital fibrocyte recruitment are involved in 
GO needs to be determined.   
Fibrocytes express marginal amounts of IGF-1R but high level of TSHR 111. 
Although the IGF-1R and TSHR expression levels were similar between circulating 
fibrocytes from GO and healthy controls, the fraction of circulating TSHR+ fibrocytes 
was increased in GO, which did not relate to disease activity or smoking history 111, 115. 
TSH and the TSHR-activating antibody M22 stimulate CCL2, CCL3, CCL4, CCL5, 
CXCL10, granulocyte colony-stimulating factor (G-CSF), IL-6, IL-8, IL-12 and TNF-D 
production by fibrocytes 111, 115. Fibrocytes do express substantially higher levels of 
TSHR and CD40 than orbital fibroblasts and produce high levels of cytokines in 
response to CD154 111, 115, 116. Fibrocytes also produce significantly more IL-6 upon 
TSHR activation than orbital fibroblasts, and this response is even more vigorous in GD 
fibrocytes 117. Possibly this is related to the increased fraction of circulating TSHR+ 
fibrocytes observed in GD patients 115.  
Besides TSHR, fibrocytes were found to express the thyroid proteins 
thyroglobulin (Tg) and thyroid peroxidase (TPO), which are also targets for autoantibody 
generation in GD 118. Fibrocytes thus potentially represent a source that can contribute 
to extra-thyroidal accumulation of thyroid proteins, for instance in orbital tissue as has 
been observed for Tg in GO 119, 120. This raises the possibility that, besides TSHR, other 
thyroid antigens expressed by fibrocytes have a role as autoantigen in the orbital tissue 
from GO patients 118, 119. 
Circulating fibrocytes produce higher levels of sIL-1RA than orbital fibroblasts 
from GO patients 121. However, when CD34+ and CD34- orbital fibroblast populations 
were sorted from parental (mixed) GO orbital fibroblast populations and subsequently 
stimulated with IL-ȕ LW DSSHDUHG WKDW WKH&'+ orbital fibroblasts exhibited greater 
capacity to produce sIL-1RA than the CD34- fibroblasts and the parental fibroblast 
population 121. Therefore it has been suggested that CD34+ orbital fibroblasts revert to 
fibrocytes when cultured in the absence of CD34- orbital fibroblasts. Consequently, the 
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authors proposed that fibrocytes that transit into CD34+ orbital fibroblasts encounter 
signals from the native CD34- orbital fibroblast population leading to a dramatic 
reduction in sIL1-RA production capacity by the CD34+ orbital fibroblasts and thus 
diminished capacity to oppose IL-Į DQG ,/-ȕ DFWLYLW\ ZLWKLQ WKH RUELW 121. Although 
attractive as a model, the currently available data are insufficient to support this 
relationship between CD34+ fibrocytes, CD34+ orbital fibroblasts, CD34- orbital 
fibroblasts and sIL-1RA and additional studies are thus required.   
Fibrocytes express the HLA-class II molecules HLA-DP and HLA-DQ at high 
level, and HLA-DQ, the co-stimulatory molecule CD86 and adhesion molecules CD11a, 
CD54 and CD58 are expressed at a level similar to that of monocytes, while the co-
stimulatory molecule CD80 is weakly expressed 122.  In line with this, fibrocytes potently 
activate CD4+ T-lymphocytes in an antigen dependent manner, suggesting that 
fibrocytes may also be involved in initiation of antigen-specific immunity 122. Whether 
fibrocytes fulfill such a role in the (auto)immune pathogenesis of GO remains unclear.         
The scant data so far available imply that fibrocytes expressing a.o. CD34, CD40 
and thyroid autoantigens, including TSHR, infiltrate orbital tissue from GO patients 
where they differentiate into CD34+ orbital fibroblasts thereby contributing to orbital 
fibroblast heterogeneity. The CD34+ orbital fibroblasts can be activated by GO 
associated autoantibodies and other inflammatory factors to contribute to inflammation 
and adipose tissue expansion. However, additional studies that aim at unraveling the 
exact contribution of fibrocytes to the pathogenesis of GO are clearly required.  
Although the disease initiating trigger is unknown so far, our understanding of the 
pathogenetic processes involved in GO has hugely increased during the last decades. 
In our current concept of the disease exaggerated orbital fibroblast activity is placed at 
the center, where these cells play a crucial role in the initiation and maintenance of the 
inflammatory response as well as in orbital tissue expansion and remodeling through 
proliferation, differentiation into adipocytes and myofibroblasts and enhanced ECM 
production. The unique hyper-responsive phenotype of orbital fibroblasts along with 
heterogeneity within the orbital fibroblast pool (e.g. Thy1+/Thy1-, fibrocytes/CD34+ 
orbital fibroblasts, but possibly also subpopulations with mesenchymal stem cell 
properties 123, 124) and the inflammatory milieu within the noncompliant space-limited 
bony orbit may very well underlie the orbital manifestations and disease course of GO. 
The contribution of orbital fibroblasts to the pathogenesis of GO is summarized in Figure 
1 and Table 1. 
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 Figure 1. The immunopathobiology of GO 
Immune cells and fibrocytes are recruited into the orbital tissue. Fibrocytes differentiate 
into CD34+ orbital fibroblasts that express IGF-1R, TSHR and other thyroid antigens, 
including thyroglobulin (Tg). Together with the Thy1- and Thy1+ orbital fibroblasts they 
constitute the heterogeneous orbital fibroblast pool. The infiltrated immune cells interact 
with the (activation-prone) orbital fibroblasts either via cell-cell interactions, involving 
molecules such as CD40 and CD154, or via secreted factors, including cytokines, 
chemokines, growth factors, and stimulatory autoantibodies (GD-IgG) directed against 
TSHR and IGF-1R. This leads to activation of the orbital fibroblasts which in turn 
contributes to orbital inflammation via the production of cytokines and chemokines and 
subsequent recruitment and activation of immune cells. Furthermore the activated 
orbital fibroblasts display increased proliferative activity, differentiate into adipocytes 
(especially Thy1- orbital fibroblasts as well as CD34+ orbital fibroblasts) or 
myofibroblasts (especially Thy1+ orbital fibroblasts as well as CD34+ orbital fibroblasts) 
and  produce increased amounts of extracellular matrix (ECM). Altogether these 
processes cause pathologic remodeling and expansion of the orbital tissue within the 
noncompliant space-limited bony orbit which contributes to the clinical features of GO.    
Thy1-/Thy1+
cytokines / growth factors
e.g. IFNJ, IL-1E, IL-4, PDGF,
TGF, TNF
proliferation
tissue expansion /
remodelling / fibrosis
tissue expansion /
remodelling / fibrosis
inflammation
adipocytemyofibroblastadipocytemyofibroblast
ECM
cytokines / chemokines
e.g. CCL2, CCL5, CXCL10,
IL-6, IL-8, IL-16, PGE2, TNF-D
GD-IgG
macrophage adipocytefibrocyte mast cell
CD154 CD34 CXCR4CD40TSHRIGF-1R ICAM-1orbital fibroblast
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Platelet-derived growth factor; an important factor in GO that may 
represent an attractive therapeutic target? 
From data discussed above it appears that PDGF isoforms, especially PDGF-AB 
and PDGF-BB, represent important growth factors in the activation of orbital fibroblasts 
in GO and thus the regulation of several major pathophysiological process in GO. 
Inhibition of PDGF activity may thus be considered as therapeutic strategy in GO and 
therefore the PDGF/PDGF receptor system is discussed in more detail. 
PDGF is a family of growth stimulating polypeptides that exerts broad functions in 
health and disease 125. There are four different PDGF genes that encode the peptide 
chains PDGF-A, PDGF-B, PDGF-C and PDGF-D 125. Disulfide bridging between PDGF 
chains results in the formation of the homodimeric molecules PDGF-AA, PDGF-BB, 
PDGF-CC and PDGF-DD or the heterodimeric PDGF-AB molecule 125. The pro-peptide 
chains of PDGF-A and PDGF-B dimerize intracellularly and have to be activated before 
secretion by removal of their N-terminal ends 125. PDGF-CC and PDGF-DD are 
secreted as latent molecules that contain CUB domains at their N-terminal ends 125. 
Activation of these PDGF isoforms occurs after proteolytic removal of the CUB domains 
by proteases such as plasmin and tissue plasminogen activator 125. 
PDGF dimers exert their biologic actions via activation of specific receptors 
consisting of two PDGF receptor (PDGF-5FKDLQVĮĮĮȕRUȕȕFKDLQV7KH3'*)-A 
and PDGF-C chains are ligands for PDGF-5ĮWKH3'*)-D chain is a ligand for PDGF-
5ȕ ZKLOH WKH 3'*)-B chain can bind both to PDGF-5Į DQG 3'*)-5ȕ EXW ZLWK D
higher affinity for PDGF-5ȕ 125. PDGF-R chains consist of an extracellular and an 
intracellular part. The extracellular part contains five immunoglobulin-like domains while 
the intracellular part consists of split kinase domains (Figure 2A). Depending on the 
PDGF ligand that binds PDGF-R chains dimerize in either one of three dimeric forms; 
ĮĮĮȕRUȕȕ )LJXUH$7KH3'*)-receptor belongs to the tyrosine kinase receptor 
family and PDGF binding is followed by autophosphorylation of crucial tyrosine residues 
within the receptor chains (Figure 2B) with subsequent activation of downstream 
signaling molecules such as RAS-MAPK, PI3K and PLC-ߛ 125, 126.  
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Figure 2. PDGF and PDGF-receptor 
A. PDGF-A and PDGF-C chains are ligands for PDGF-5Į3'*)-D chain is a ligand for 
PDGF-5ȕZKLOHWKH3'*)-B chain can bind both to PDGF-5ĮDQG3'*)-5ȕ'RWWHG
lines indicate weak interactions or conflicting results 125. B. Autophosphorylation of 
crucial tyrosine residues within the receptor chain results in the activation of 
downstream signaling molecules. 
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In normal physiology, PDGF signaling fulfills important roles in organogenesis, 
organ/tissue homeostasis and wound healing processes. For instance, PDGF-signaling 
is involved in alveogenesis, villus morphogenesis, spermatogenesis, nephrogenesis, 
angiogenesis, glomerulogenesis, tooth morphogenesis and development of dermis and 
lens 125. Also in wound healing different PDGF isoforms play an important role as they 
recruit and activate neutrophils, macrophages and fibroblasts, thereby facilitating the 
tissue remodeling process 127. However, sustained or elevated PDGF production and 
signaling is associated with many different diseases including cancers, vasculopathy 
and fibrosis 125, 128. A general characteristic of tissue fibrosis is excessive fibroblast 
activity with resultant hyperproliferation and extracellular matrix production by these 
cells, processes highly stimulated by PDGF isoforms and all contributing to GO as well. 
Data described before indicate that in GO PDGF-AA, but especially PDGF-AB and 
PDGF-BB, stimulate proliferation, hyaluronan and cytokine/chemokine production and 
TSHR expression by orbital fibroblasts (Figure 3). This, along with the elevated 
expression of PDGF-A and PDGF-B chains in orbital tissue during all GO disease 
stages, indicates that inhibition of PDGF signaling may represent as an attractive way 
for treatment of GO. However this requires further investigation into effects of PDGF on 
other aspects of orbital fibroblast activation. This holds especially true for adipogenesis 
in GO, which is a major contributor to orbital tissue expansion while opposite effects of 
PDGF on adipogenesis of fibroblasts and pre-adipocytes from different anatomical sites 
have been described 129, 130.  
 
 
Figure 3. Role of PDGF signaling in GO.  
Monocytes, macrophages and mast cells produce PDGF-A and PDGF-B chains in 
orbital tissue from GO, resulting in the formation of PDGF-AA, PDGF-AB and PDGF-BB 
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dimeric molecules. These PDGF-isoforms stimulate proliferation, cytokine and 
hyaluronan production by orbital fibroblasts while PDGF-AB and PDGF-BB also 
enhance TSHR expression on orbital fibroblasts. In general PDGF-BB is the PDGF-
isoform exhibiting the most potent effect on orbital fibroblasts, while PDGF-AA is the 
weakest.    
    
7UHDWPHQW RI *UDYHV¶ RSKWKDOPRSDWK\ LV LQKLELWLRQ RI 3'*)
activation a possibility? 
Currently, the most effective well-tolerated treatment for active moderate-to-
severe and sight-threatening GO is (high dose) corticosteroids, while radiotherapy or 
orbital decompression surgery are considered when patients fail to respond to 
corticosteroids or for rehabilitating purposes 131, 132. Effectiveness of corticosteroid 
treatment relies mainly on the activity of the disease, with a high success rate when 
introduced in the initial active inflammatory phase of the disease 131, 132. However, 
corticosteroid treatment may negatively influence the tissue remodeling or fibrotic phase 
when inflammation has subsided 132. Corticosteroids, such as dexamethasone, 
stimulate PDGF-B production by macrophages and enhance PDGF-5ĮH[SUHVVLRQRQ
fibroblasts, which augments fibroblast effector functions in lung fibrosis 133-135. In 
contrast to the ambivalent effects that corticosteroids can have with regard to 
inflammation, tissue remodeling and fibrosis, the ideal therapy for GO should be 
effective regardless of the stage of disease. However, so far novel medical treatment 
options for GO have mainly concentrated on therapeutics directed at immune cells (e.g. 
B-lymphocytes; rituximab) or mediators (e.g. TNF-Į HWDQHUFHSW WKDW PDLQO\ DUH
involved in the active inflammatory phase of GO 136, 137. 
PDGF targeting seems an attractive therapeutic option in GO, as PDGF-driven 
orbital fibroblast activation most likely occurs in all stages of GO (Figure 4). Several 
approaches to interfere with PDGF-signaling in GO can be thought of : 1) neutralization 
of PDGF-molecules, for instance with specific neutralizing antibodies or soluble receptor 
molecules, 2) blockage of the PDGF-receptor chains with neutralizing antibodies or 
dominant negative ligands and 3) inhibition of PDGF-receptor signaling by using 
tyrosine-kinase inhibitors that prevent receptor autophosphorylation upon ligand binding 
(Figure 5) 125.  
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Figure 4. A hypothetical scheme of the pathophysiology and treatment of GO.  
Early GO is characterized by a Th1-dominated inflammatory environment which leads to 
massive orbital tissue inflammation and edema. In time, this Th1 environment is skewed 
towards a Th2-dominated environment in which inflammation subsides, but fibrotic 
tissue remodeling continues. Current mainstream treatment of GO consists of 
corticosteroids and surgery, of which the corticosteroids have a relatively a high 
success rate when introduced in the active inflammatory phase of the disease, but may 
negatively influence the tissue remodeling or fibrotic phase when inflammation has 
subsided. Surgery may be effective in early/active stages of GO, but is predominantly 
used for rehabilitation of GO patients. Increased PDGF activity contributes to all stages 
of GO and inhibition of PDGF activity may therefore be effective in all stages of GO. 
Figure 5. Approaches to target PDGF signaling.  
The PDGF system can be blocked by targeting the PDGF molecule, for instance with a 
neutralizing antibody, or by targeting the PDGF-Receptor, for instance with a 
neutralizing antibody or a tyrosine kinase inhibitor with specificity for the PDGF-
Receptor. 
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receptors are currently not available for clinical use, such an approach might be of 
benefit in the treatment of GO as it was found that a neutralizing antibody directed 
towards PDGF-BB reduced IL-6 and hyaluronan secretion by orbital tissue from GO 
patients in a newly developed orbital tissue culture approach 10. Remarkably, in this 
culture system inhibition of PDGF-AA with a neutralizing antibody was hardly effective, 
underlining the importance of PDGF-B chain containing PDGF isoforms in the 
pathophysiology of GO.  
Several tyrosine kinase inhibitors (TKIs) that exhibit specificity for the PDGF-
receptor, amongst which imatinib mesylate and nilotinib, are widely applied to treat 
BCR-ABL positive chronic myeloid leukemia (CML) as the tyrosine kinase ABL is a 
target for these TKIs as well 138. In addition, imatinib mesylate has been used 
successfully to treat gastrointestinal tumors and mastocytosis by targeting c-Kit kinase 
activity 139, 140. Imatinib mesylate and nilotinib were both found to prevent PDGF-induced 
TSHR expression, proliferation, cytokine and hyaluronan production by orbital 
fibroblasts from GO patients 10, 33, 49, 83. Moreover, imatinib mesylate attenuated IL-6 and 
hyaluronan secretion by cultured GO orbital tissue, while the TNF-ĮQHXWUDOL]LQJDJHQW
adalimumab only reduced IL-6 secretion 141. Although these data point at the 
attractiveness of TKI usage in the treatment of GO, imatinib mesylate and nilotinib were 
found to cause serious side effects such as peri-orbital edema, peripheral arterial 
occlusive disease and cerebrovascular events in CML treatment 142. Moreover, it was 
recently shown that imatinib mesylate can stimulate adipogenesis by orbital fibroblasts 
69, although this was at high imatinib mesylate concentration. Based on the described 
adverse effects, imatinib mesylate and nilotinib are not directly regarded as candidate 
TKIs for a clinical study in GO, at least not when applied in the same dose as used for 
CML treatment. Therefore studies into other TKIs that inhibit PDGF-R activity in (GO) 
orbital fibroblasts are warranted.  For instance, dasatinib which is associated with less 
severe side effects than imatinib mesylate 143, 144. Interestingly, recent studies 
demonstrated efficacy of nintedanib (a TKI with high specificity for PDGF-R but also 
FGF and VEGF receptors) in the treatment of idiopathic pulmonary fibrosis, a form of 
pulmonary fibrosis that involves elevated PDGF, FGF and VEGF activity and for which 
no suitable treatment was available to date 145, 146. Although FGF and VEGF have been 
suggested to contribute to GO their effects on orbital fibroblast activity are poorly 
studied to date 147-150. Therefore further studies into the orbital fibroblast activating 
effects of FGF and VEGF, along that of PDGF, and the effect of nintedanib on this are 
warranted 147, 149. 
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 The aims of this thesis are:
 a) to examine the effect of PDGF-BB, either alone or in conjuction with basic
  fibroblast growth factor (bFGF) and vascular endothelial growth factor
  (VEGF) on several aspects of orbital fibroblast activity involved in GO
 b) to determine wheter this fibroblast activation can be blocked by different
  clinically available tyrosine kinase inhibitors and
 c) to examine the effect of the mast cell mediator histamine on orbital fibroblast
  activity. 
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Abstract 
 
Background 

GraveV¶ ophthalmopathy (GO) remains hard to treat. Excessive orbital fibroblast 
activation by platelet-derived growth factor (PDGF)-BB contributes to GO. The tyrosine 
kinase inhibitors (TKIs) imatinib mesylate and dasatinib both target PDGF-receptor 
tyrosine kinase activity, albeit with a different potency. We compared the efficacy of 
these TKIs on PDGF-BB-induced proliferation, and on cytokine and hyaluronan 
production by orbital fibroblasts. Also the capacity of dasatinib to suppress GO- 
associated gene expression in orbital tissue was examined. 

Methods 

Orbital fibroblasts from four GO patients and five control subjects were used. The 
efficacy of the two TKIs was tested by: 1) pre-incubating orbital fibroblasts 
overnight with different TKI concentrations, followed by 24 h stimulation with PDGF-BB, 
2) adding TKI and PDGF-BB simultaneously to the orbital fibroblasts in 24 h cultures. 
Proliferation was assessed by colorimetric assay. Hyaluronan and cytokine production 
were measured by ELISA. Furthermore, orbital tissue was obtained from a patient with 
active GO, and the effect of dasatinib on the expression levels of HAS2-, CCL2-, IL6-, 
and IL8- mRNA expression was examined by real-time quantitative PCR. 
 
Results 
 
Pre-incubation of orbital fibroblasts with imatinib mesylate or dasatinib resulted in 
significant and dose-dependent inhibition of PDGF-BB-induced orbital fibroblast 
proliferation, and hyaluronan and cytokine production. Dasatinib exhibited these effects 
at far lower concentrations. The same results were observed in the setting where TKI 
and PDGF-BB treatments were commenced simultaneously. In orbital tissue from 
active GO, dasatinib significantly suppressed HAS2-, CCL2-, IL6- and IL8-mRNA 
levels. 
 
Conclusion 
 
Dasatinib may be a promising alternative to high-dose steroids in the treatment of 
GO. 
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Introduction 
 
*UDYHV¶GLVHDVH*'LVRQHRIWKHPRVWFRPPRQDXWRLPPXQHGLVRUGHUVDQGDFFRXQWV
for ~80% of the total cases of hyperthyroidism in the Western world and iodine-sufficient 
regions. Clinical manifestations of GD result from stimulatory autoantibodies directed 
against the thyroid stimulating hormone receptor (TSHR). These autoantibodies target 
the thyroid gland where they stimulate thyroid hormone production 1. Between 25-50 % 
RI *' SDWLHQWV GHYHORS VRPH GHJUHH RI *UDYHV¶ RSKWKDOPRSDWK\ *2 ZKLFK LV
characterized by orbital tissue inflammation and expansion 2. Increased orbital fibroblast 
proliferation, and enhanced production of extracellular matrix (ECM) components 
(especially hyaluronan) and cytokines by these cells constitute key events in the 
pathophysiology of GO and contribute to clinical manifestations such as chemosis, 
edema, proptosis and ocular motility dysfunction 3. GO often constitutes a considerable 
physical and mental burden. Unfortunately, however, no clear improvement in treatment 
has been achieved during the last decades, and it still mostly consists of anti-
inflammatory therapy with corticosteroids 4 or orbital decompression surgery. However, 
this treatment is often a high burden for patients, due to accompanying side-effects of 
corticosteroid treatment. Moreover, a significant number of patients fail to respond to 
these therapies. Although biologicals such as etanercept 5 or infliximab 6, that 
specifically neutralize TNF-Į RU ULWX[LPDE 7, that depletes B-cells, initially showed 
promising results in GO, other treatment options for GO are eagerly needed, as 
experience with these compounds in clinical practice in GO is limited and results are 
contradictory 7, 8. 
Platelet-derived growth factor (PDGF) is important in normal wound healing, and 
increased levels or activity of PDGF have been shown to be involved in pulmonary, 
liver, dermal and cardiac fibrosis, in which it primarily acts as a mitogen for fibroblasts 
with a myofibroblast phenotype 9. Previously we identified PDGF-BB and PDGF-AB as 
important contributors to GO as well. The level of these growth factors is increased in 
orbital tissue from GO patients. There they potently stimulate proliferation and 
production of cytokines such as CCL2, IL-6 and IL-8 as well as hyaluronan by orbital 
fibroblasts 10-12. PDGF isoforms thus stimulate several key pathogenic pathways in GO. 
Therefore, they represent attractive therapeutic targets for the treatment of GO.  
Imatinib mesylate and nilotinib are small molecule tyrosine kinase inhibitors (TKI) 
that block c-Abl kinase activity. They are used to inhibit the constitutive Abl kinase 
activity of the BCR-ABL fusion protein in chronic myeloid leukemia 13. In addition, 
imatinib mesylate and nilotinib inhibit PDGF receptor (PDGF-R) tyrosine kinase activity 
and thereby can prevent PDGF-induced PDGF-R autophosphorylation and signaling, 
also in orbital fibroblasts 11. Recently, we demonstrated that imatinib mesylate and 
nilotinib block PDGF-BB and PDGF-AB induced proliferation, hyaluronan and cytokine 
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production by orbital fibroblasts 10-12. Moreover, we found that imatinib mesylate 
reduced IL-6 and hyaluronan production in whole orbital tissue cultures from GO 
patients, which correlated with the PDGF levels present in the tissue 14. This further 
supports our notion that suppression of the PDGF-signaling cascade represents an 
attractive therapeutic target in GO. However, treatment of chronic myeloid leukemia with 
imatinib mesylate or nilotinib is associated with serious side effects such as peri-orbital 
edema, peripheral arterial occlusive disease and cerebrovascular events 15. Imatinib 
mesylate and nilotinib may therefore not represent the preferable type of medication for 
GO, at least not when given in dosages comparable to those used to treat chronic 
myeloid leukemia. Nevertheless, considering the attractiveness of targeting the PDGF 
pathway in GO, PDGF-R targeting with TKI other than imatinib mesylate or nilotinib 
might constitute potential therapeutic options in GO.  
Dasatinib is a TKI which is structurally distinct from imatinib mesylate and 
nilotinib. Although dasatinib is a less specific TKI than imatinib mesylate and nilotinib, it 
displays a considerably higher inhibitory potency (pIC50)  for the PDGF receptor, both 
PDGF-5Į DQG 3'*)-5ȕ FKDLQ WKDQ imatinib mesylate and nilotinib 13. Dasatinib is 
currently approved as second-line therapy for treatment of chronic myeloid leukemia, 
with a more beneficial outcome and fewer side effects than imatinib mesylate 16, 17. 
Dasatinib has also been tested for treatment of bleomycin-induced dermal fibrosis in 
mice. It was found to decrease skin thickness, myofibroblast numbers and collagen 
production in this model in which PDGF signaling is highly active 18. Moreover, dasatinib 
reduced the production of the ECM components fibronectin and collagen by skin 
fibroblasts from a systemic sclerosis patient 18. Interestingly, dasatinib suppressed 
nucleic acid-induced interferon production by plasmacytoid dendritic cells from patients 
with auto-immune diseases such as systemic lupus erythematosus and psoriasis at 
much lower concentrations than imatinib mesylate did 19. The level of biochemical 
activity between different TKI may thus clearly differ within a specific cell type.  
Dasatinib might thus be effective at a lower dosage for treatment of auto-immune 
disease than that required for treatment of chronic myeloid leukemia, suggesting that 
less severe side effects can be expected as well. Therefore, the aim of this study was to 
determine the effect of wide concentration ranges of imatinib mesylate and dasatinib on 
PDGF-BB±induced proliferation, cytokine and hyaluronan production by orbital 
fibroblasts to provide an in vitro basis for TKI-based treatment of GO patients. 

 
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analyzed using the paired t-test. P < 0.05 was considered statistically significant. Data 
are presented as the mean ± standard error of the mean (SEM). 
assessed after 24 hours by colorimetric assay based on the uptake and subsequent 
release of methylene blue dye. Proliferation was calculated as percentage above control 
by comparing stimulated to unstimulated conditions as described before 11. 
 
Hyaluronan, CCL2, IL-6 and IL-8 production by orbital fibroblasts 
Orbital fibroblasts were seeded at 5.0 x 104 cells/well into 12-well plates in 
DMEM 10% FCS and allowed to grow until fully confluent monolayers were established. 
Then, the cultured orbital fibroblast monolayers were put overnight in DMEM 1% FCS. 
The effect of imatinib mesylate and dasatinib on PDGF-BB-induced hyaluronan, CCL2, 
IL-6 and IL-8 production was studied, again both for TKI pre-incubation and 
simultaneous treatment with TKI and PDGF-BB.  Supernatant was collected after 24 
hours of stimulation with PDGF-BB (50 ng/ml) and the amount of hyaluronan, CCL2, IL-
6 and IL-ZDVGHWHUPLQHGE\(/,6$DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO 
 
HAS2, CCL2, IL6 and IL8 mRNA expression by whole orbital tissue in culture 
Orbital tissue was obtained from a patient who underwent emergency orbital 
decompression surgery because of active GO (clinical activity score: 3/7) despite 
intravenous corticosteroid treatment. Orbital tissue was divided into two parts. One part 
was cultured overnight in the presence of dasatinib while the other part was cultured in 
the absence of dasatinib in DMEM 1% FCS. For this proof of principle experiment 
examining the effectiveness of dasatinib on active GO tissue, dasatinib was used in a 
concentration of 2.5 g/ml. RNA was isolated using GenElute Mammalian Total RNA 
0LQLSUHS .LW DFFRUGLQJ WR PDQXIDFWXUHU¶V SURWRFRO 6LJPD-Aldrich, St Louis, MO) and 
was reverse transcribed into cDNA 11.  HAS2 (Hyaluronan synthase 2), CCL2, IL6 and 
IL8 mRNA expression levels were determined in triplicate by real-time quantitative PCR 
(7900 PCR system; Applied Biosystems, Foster City, CA) and the analyzed gene 
transcripts were normalized to the control gene ABL. CCL2 mRNA level was determined 
with commercially available primer-probe assay (TaqMan Gene Expression Assays 
Hs00234140_m1, Life technologies, Foster City, CA). Other primer-probe combinations 
used are listed in table 1 11, 12. 
 
Statistical analysis 
Differences between unstimulated or stimulated orbital fibroblasts with PDGF-BB, 
and with or without TKI were analyzed using the Mann-Whitney U test. Differences in 
gene expression level in orbital tissue with and without dasatinib incubation were 
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 Control orbital fibroblasts (COF, upper panels) and GO orbital fibroblasts (GO,
lower panels) were cultured in nondifferentiation medium (left column), adipocyte
differentiation medium (middle column), and adipocyte differentiation medium in the
presence of PDGF-BB (50 ng/mL, right column). Oil-Red-O staining was performed after
14 days of differentiation. Representative COF and GO orbital fibroblasts are depicted.
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Effect of IL-6±Receptor Neutralization on PDGF-BB±Induced Adipogenesis 

Platelet-derived growth factor±BB can stimulate orbital fibroblasts to produce IL-6, a 
cytokine previously associated with increased adipogenesis by orbital 
fibroblasts.5,6,14 Therefore, we measured IL-6 secretion by the orbital fibroblasts in the 
culture medium. Orbital fibroblasts cultured for 3 days in differentiation medium 
secreted significantly (P < 0.01) higher levels of IL-6 compared to culture in 
nondifferentiation medium. The IL-6 levels were increased further (P < 0.0001 
compared to differentiation medium) when PDGF-BB was added to the differentiation 
medium (Fig. 4A). The level of IL-6 secretion declined thereafter, with equal levels 
between the different culture conditions at days 7, 10, and 14 (Fig. 4A). The 
adipogenesis-enhancing effect of PDGF-BB, however, was not blocked by an IL-6-
receptor neutralizing antibody (Fig.  4B). Interleukin-6±enhanced adipogenesis did 
not differ statistically from that of PDGF-BB± enhanced adipogenesis, but was 
significantly (P < 0.01) reduced by the IL-6 receptor neutralizing antibody (Fig. 4C). 
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Interleukin-6 serum levels were found to be increased in GO patients compared to 
Graves'  disease  patients  without  GO,25 and  orbital  tissue  IL-6  levels  have  been 
described   to   correlate   positively   with    orbital   adipose   tissue   expansion   
in GO.26 Moreover,  IL-6  enhances  TSHR  expression  by  orbital  fibroblasts  
cultured  in adipocyte differentiation medium, and enhanced adipogenesis is 
presumed to represent the main route of elevated TSHR expression by orbital 
fibroblasts in GO.14,27 In our previous studies we found that PDGF-BB stimulated IL-6 
production by orbital fibroblasts5,28 and here we demonstrated that IL-6 promotes 
adipogenesis of orbital fibroblasts. Nevertheless, the adipogenesis-enhancing effect 
of PDGF-BB was not prevented by IL-6±receptor blockade, indicating that pathways 
other than induction of autocrine  IL-6  signaling  also  are  involved  in  the  
adipogenesis-enhancing  effect  of PDGF-BB. Platelet-derived growth factor signaling 
results in activation of kinase activity of the signaling molecule c-ABL.29,30 Recently c-
ABL activity was found to control the expression and activity of PPAR-Ȗ and appeared 
to be indispensable for adipocyte differentiation by murine 3T3-L1 preadipocytes.31 
Therefore, it cannot be excluded that PDGF-BB±driven adipocyte differentiation by 
orbital fibroblasts involves c-ABL activity. 

The adipogenesis-enhancing effect of PDGF-BB on orbital fibroblasts was 
abrogated by a low concentration (0.04 ȝg/mL) of dasatinib, a clinically available TKI 
that exhibits high inhibitory potency (pIC50) for the PDGF-receptor,10 as well as by 
the specific PDGF receptor  TKI  tyrphostin  AG1296.  Moreover,  dasatinib  also  
downregulated  PPAR-ȖmRNA expression in cultured GO orbital tissues. This effect 
of dasatinib in the orbital tissue culture experiments did not reach statistical 
significance (P = 0.08), which is most likely related to the small number of tissues 
tested (n = 3). Nevertheless, the data clearly  illustrated  the  potential  of  dasatinib  
in  targeting  adipogenesis  in  GO,  and inhibition of the PDGF-receptor might be 
involved in this. As dasatinib not only targets the PDGF-receptor tyrosine kinase, we 
cannot exclude that dasatinib targeted other tyrosine kinase molecules in the orbital 
tissue as well.10 

Previously, we proposed that PDGF-receptor targeting TKI could be of potential 
interest for the treatment of GO to block PDGF-induced cytokine and hyaluronan 
production, proliferation, and TSHR expression by orbital fibroblasts.4,28 These data 
and our current findings suggest that PDGF-receptor inhibition in GO can be expected 
to target several pathological processes in GO, including adipogenesis. However, it 
also has been described that imatinib mesylate, another TKI that inhibits the PDGF-
receptor, at a concentration of 5 ȝg/mL enhances adipogenesis by orbital fibroblasts 
cultured under pathological pressure.32 Also proadipogenic effects of imatinib 
mesylate and dasatinib on multipotent mesenchymal stromal cells have been 
described.33,34 In contrast to this, imatinib mesylate at a concentration of 2.5 ȝJ/mL 
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(the highest nontoxic concentration in our hands) blocked adipogenesis by orbital 
fibroblasts in our culture system (Supplementary Fig. S1), although not as efficient as 
dasatinib at that concentration. Although these differences may be related to different 
methodological approaches between studies, it stresses our incomplete 
understanding of GO pathogenesis and orbital fibroblast biology, and indicates that 
novel drugs to treat GO, such as TKI, should be implemented with caution. However, 
alternative approaches to interfere with PDGF signaling in GO can be thought of, for 
instance via PDGF-neutralization with specific neutralizing antibodies or soluble 
receptor molecules, or blockage of the PDGF-receptor with neutralizing antibodies or 
dominant negative ligands.1 

In summary, we report that PDGF-BB enhances adipogenesis by orbital 
fibroblasts exposed to a proadipogenic culture environment. Therefore, PDGF-BB can 
be expected to contribute to the orbital adipose tissue expansion in GO. 
Collectively, our previous observations of elevated orbital PDGF-BB expression in 
GO, the stimulatory effects of PDGF-BB on proliferation, cytokine, and hyaluronan 
production, and TSHR expression by orbital fibroblasts, and our current finding that 
PDGF-BB enhances adipogenesis suggests that PDGF-BB represents an important 
contributor to the pathogenesis of GO. Consequently, PDGF-BB, the PDGF-receptors 
and their downstream signaling molecules may represent potential targets for therapy 
in GO. 

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
Supplemental  figure  1.  Effect of tyrosine kinase inhibitors on adipogenesis in 
orbital fibroblasts. A: Oil-Red-O staining was quantified in eluate from orbital 
fibroblasts (controls n=2, GO patients n=2) cultured for 14 days in non-
differentiation medium or adipocyte differentiation medium either in the presence or 
absence of imatinib mesylate or dasatinib (both 2.5ȝg/ml). B: PPAR-Ȗ mRNA 
expression was determined by RQ-PCR in orbital fibroblasts from controls (n=2) 
and GO patients (n=2) cultured for 14 days in non-differentiation medium or 
adipocyte differentiation medium either in the presence or absence of imatinib 
mesylate or dasatinib. Each dot represents the orbital fibroblast strain from one 
individual and horizontal bars represent the mean values within a group. Data were 
analyzed using the paired StudeQW¶V t-test. * and ** represent p value of < 0.05 and 
< 0.01, respectively. 
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
Figure 3. PDGF-BB, but not bFGF and VEGF, stimulates IL-6 production by 
orbital fibroblasts. 

Orbital fibroblasts from GO (n=2-4) and controls (n=2) were stimulated with 
recombinant human PDGF-BB (circle), bFGF (square) or VEGF (triangle) at 
indicated concentrations. IL-6 levels were assessed after 24 (A) and 48 (B) hours 
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Results 

The effect of PDGF-BB and bFGF on PDGF-A, PDGF-B and bFGF mRNA 
expression by orbital fibroblasts 

PDGF-A mRNA expression was transiently induced by PDGF-BB (P <0.05) reaching 
the peak at 2 hours while bFGF appeared to significantly downregulate PDGF-A 
mRNA expression by orbital fibroblasts after 4 hours (Figure 1A). Co-stimulation of 
orbital fibroblasts with PDGF-BB and bFGF revealed PDGF-A mRNA kinetics 
comparable to that observed with PDGF-BB stimulation alone (Figure 1A). PDGF-B 
mRNA expression was transiently induced by PDGF-BB (P <0.05) and bFGF (P 
<0.05), but the level of induction was significantly higher for PDGF-BB than bFGF 
stimulation (P <0.05), reaching peak levels at 2 and 4 hours, respectively (Figure 1B). 
Co-stimulation of orbital fibroblasts with PDGF-BB and bFGF did not result in significant 
higher induction of PDGF-B mRNA compared to stimulation with PDGF-BB alone, but 
was associated with a less rapid decrease of the elevated PDGF-B mRNA levels over 
the period between 2 and 24 hours after stimulation (Figure 1B, grey area). PDGF-BB 
stimulation did not impact bFGF mRNA expression levels in orbital fibroblasts 
while bFGF appeared to significantly downregulate bFGF mRNA expression by 
orbital fibroblasts after 4 hours (Figure 1C). However, co-stimulation of orbital 
fibroblasts with PDGF-BB and bFGF transiently induced bFGF mRNA expression (P 
<0.05) reaching the peak at 4 hours (Figure 1C). No increase in PDGF-BB and bFGF 
protein levels was observed in culture supernatants from orbital fibroblasts co-
stimulated with PDGF-BB and FGF after 12 and 24 hours, as determined by ELISA 
(data not shown). 


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
Figure 1. PDGF-A, PDGF-B and bFGF mRNA expression upon PDGF-BB 
and/or bFGF stimulation. 

Orbital fibroblasts from three GO patients were stimulated with recombinant human 
PDGF-BB (50 ng/ml; circle), bFGF (20 ng/ml; square) or PDGF-BB+bFGF (triangle) for 
1, 2, 4, 6 and 24 hours. Transcript levels of PDGF-A (A), PDGF-B (B) and bFGF (C) 
mRNA were determined by RQ-PCR and normalized to the control gene ABL. Results 
are presented as the mean value with error bars indicating the standard error of the 
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mean (SEM). Data were analyzed using ANOVA followed by Mann Whitney U test. *, # 
and $ indicate a p-value of <0.05 compared to the unstimulated condition. 
 
Effect of PDGF-BB neutralization on IL-6 production by orbital fibroblasts upon 
PDGF-BB and/or bFGF stimulation 

Because the mRNA data suggest that orbital fibroblast stimulation with the combination 
of PDGF-BB and bFGF may result in prolonged autocrine PDGF-BB exposure we 
examined the effect of a PDGF-BB neutralizing antibody on IL-6 production. PDGF-BB 
strongly induced IL-6 production by orbital fibroblasts (P <0.01) and the stimulatory 
effect of PDGF-BB was abrogated (P <0.01) by the highest concentration (5ug/ml) of 
the neutralizing antibody (Figure 2A). bFGF slightly enhanced IL-6 production by orbital 
fibroblasts, which was not affected by the PDGF-BB neutralizing antibody (Figure 2B). 
In line with our previous finding, co-stimulation of orbital fibroblasts with PDGF-BB and 
bFGF resulted in higher production of IL-6 compared to that induced by PDGF-BB 
alone, and this was blocked by the highest concentration of the PDGF-BB neutralizing 
antibody,  (P <0.01; Figure 2C) up to levels found with bFGF stimulation alone. In all 
cases no effect was observed with the low concentration of PDGF-BB neutralizing 
antibody nor with the isotype control at both concentrations analyzed (Figure 2 and 
Supplemental figure 1). Also at the mRNA level co-stimulation with PDGF-BB and 
bFGF resulted in greater induction of IL6 mRNA than that induced by PDGF-BB alone, 
although this did not reach statistical significance (P = 0.2; Figure 2D). The PDGF-BB 
neutralizing antibody inhibited the effect of PDGF-BB/bFGF co-stimulation up to the 
level induced by bFGF alone (Figure 2D).  
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
Figure 3. The effect of neutralizing PDGF-BB antibody on PDGF-BB and/or bFGF- 
induced hyaluronan production by orbital fibroblast. 

(A-C) Orbital fibroblasts from GO (n=3) and controls (n=2) were stimulated with 
recombinant human PDGF-BB (50 ng/ml) and/or bFGF (20 ng/ml) in the presence or 
absence of PDGF-BB neutralizing antibody or goat IgG control at concentrations of 0.5 
or 5.0 g/ml. Hyaluronan levels were assessed after 48 hours by ELISA. (D) Orbital 
fibroblasts from three GO patients were stimulated with recombinant human PDGF-BB 
(50 ng/ml) and/or bFGF (20 ng/ml) in the presence or absence of PDGF-BB 
neutralizing antibody at concentrations of 0.5 or 5.0 g/ml for 6 hours. Transcript levels 
of HAS2 mRNA expression were determined by RQ-PCR and normalized to the control 
gene ABL. Results are presented as the mean value with error bars (SEM). Data were 
analyzed using ANOVA followed by Mann Whitney U test. * and ** indicate a p-value of 
<0.05 and <0.01, respectively. 
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Discussion 

In GO orbital fibroblasts will encounter activation signals by different mediators at once, 
and once these activation signals are integrated by the orbital fibroblast they may result 
in a biological response different from that induced by a single mediator 1. PDGF-BB 
and bFGF have been proposed to contribute to GO 4, 7. Previously we reported that 
PDGF-BB and bFGF synergistically enhanced IL-6 but especially hyaluronan 
production by orbital fibroblasts. In this study we showed that co-stimulation of orbital 
fibroblasts with PDGF-BB and bFGF prolonged the duration of elevated PDGF-B 
mRNA levels in the orbital fibroblasts compared to stimulation with PDGF-BB or bFGF. 
Studies with a PDGF-BB neutralizing antibody inhibited the synergistic effect of PDGF-
BB/bFGF co-stimulation on IL-6 and hyaluronan production up to the level of that induced 
by bFGF alone. Our data therefore support involvement of autocrine PDGF-BB 
signaling in the synergistic enhancement of IL-6 and hyaluronan when orbital 
fibroblasts are co-activated with PDGF-BB and bFGF. 

In this study we observed prolonged PDGF-B mRNA expression in orbital 
fibroblasts co-stimulated with PDGF-BB and bFGF compared to PDGF-BB or bFGF 
stimulation alone. Unexpectedly we could not detect elevated PDGF-BB levels in the 
culture supernatants after orbital fibroblasts were stimulated for 12 or 24 hours with 
PDGF-BB and bFGF (Supplemental figure 2). Similarly, although mRNA expression 
data revealed an induction of PDGF-B mRNA expression upon bFGF stimulation, 
PDGF-BB was also not detected by ELISA from the supernatant when culturing orbital 
fibroblasts with bFGF. Although this lack of PDGF-BB detection might be related to 
technical limitations of the detection assay used or the experimental set-up, the data 
generated with the neutralizing PDGF-BB antibody support involvement of PDGF-BB 
produced and secreted by the orbital fibroblasts when co-stimulated with PDGF-BB 
and bFGF.  
 
In our previous study (manuscript submitted, chapter 5) we could not find an 
effect of PDGF-BB on FGFR1 mRNA expression nor of bFGF on PDGFRA/B mRNA 
expression at all time points observed in this study, which is in contrast to other 
studies, 10, 11. It is however well recognized that orbital fibroblasts have unique 
features and can respond differently to specific stimuli than fibroblasts from other 
anatomical regions 17. Previous studies from our group revealed a positive 
correlation between PDGFR mRNA levels and protein expression in human retinal 
pigment epithelial cells 18 which is in line with a study in human dermal fibroblasts 
and neuroblastoma cell lines 19, 20. Although PDGFR protein expression was not 
examined in our current study and a PDGFB knockout orbital fibroblast model is not 
available to date it is so far tempting to hypothesize that the combined effect of bFGF 
and PDGF-BB on hyaluronan and IL-6 production involves prolonged autocrine 
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PDGF-BB signaling that is not regulated by changes in PDGF-receptor expression. 
 
The effect of bFGF alone on hyaluronan and to a lesser extend IL-6 production 
by the orbital fibroblasts was not inhibited by the PDGF-BB neutralizing antibody, 
despite the small enhancement in PDGF-B mRNA expression induced by bFGF (figure 
1B). Moreover, the PDGF-BB neutralizing antibody inhibited the synergistic effect of 
PDGF-BB/bFGF up to the level of that induced by bFGF alone. This clearly indicates that 
bFGF induces effects that are independent of induction of PDGF-BB production by the 
orbital fibroblasts. Comparable, PDGF-BB independent effects of bFGF on skeletal 
muscle growth and differentiation have been described 21. From our data it cannot be 
ruled out that a process like PDGFR transactivation is involved in bFGF-induced 
hyaluronan production 14. This is however unlikely as we previously observed that the 
tyrosine kinase inhibitor (TKI) dasatinib that inhibits the tyrosine kinase activity of the 
PDGFR but not FGFR did not inhibit bFGF-induced hyaluronan and IL-6 production by 
orbital fibroblasts (manuscript submitted, Chapter 5).    
 
Several studies suggested tyrosine kinase inhibitors (TKI) that inhibit the 
PDGFR, including imatinib mesylate and dasatinib, as potential drugs for the treatment 
of GO 2, 7, 22. Also PDGF-BB neutralizing antibodies, that are currently however not yet 
available for clinical application, can be considered as potential treatment option for GO 
4, 23. However these approaches cannot be expected to completely interfere with the 
effect of bFGF on hyaluronan and IL-6 production by orbital fibroblasts which fits our 
previous notion that therapy directed at the inhibition of both bFGF- and PDGF-induced 
orbital fibroblast activity may be of interest for the treatment of GO, for instance with a 
TKI that targets both the FGF-receptors and PDGF-receptors. 
 
In conclusion, we demonstrate that the synergistic effect of bFGF and PDGF-BB 
on hyaluronan and IL-6 production by orbital fibroblasts involves prolonged PDGF-BB 
production and thus autocrine PDGF-BB signaling by orbital fibroblasts.  



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

Supplemental  figure  1.  The effect of isotype control antibody on PDGF-BB 
and/or bFGF-induced IL6 and HAS2 mRNA expression by orbital fibroblast. 

Orbital fibroblasts from three GO were stimulated with recombinant human PDGF-BB 
(50 ng/ml) and/or bFGF (20 ng/ml) in the presence or absence of goat IgG control at 
concentrations of 0.5 or 5.0 g/ml for 6 hours. Transcript levels of IL6 (A) and HAS2 
(B) mRNA expression were determined by RQ-PCR and normalized to the control 
gene ABL. Results are presented as the mean value with error bars (SEM). Data were 
analyzed using ANOVA followed by Mann Whitney U test. 
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
Supplemental figure 2. PDGF-BB production upon PDGF-BB and/or bFGF 
stimulation. 

Orbital fibroblasts from GO (n=4) and controls (n=2) were stimulated with recombinant 
human PDGF-BB (50 ng/ml) and/or bFGF (20 ng/ml). PDGF-BB levels were assessed 
after 12 and 24 hours by ELISA. Results are presented as the mean value with 
error bars (SEM). Data were analyzed using ANOVA followed by Mann Whitney U test. 

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Chapter 7
Histamine induces NF-ɄB controlled
cytokine secretion by orbital fibroblasts
via histamine receptor type-1
Sita Virakul1,2, Tanachapon Phetsuksiri1, Conny van Holten–Neelen1, Benjamin Schrijver 1,
L. van Steensel1, Virgil A.S.H. Dalm1, Dion Paridaens3, Willem A. van den Bosch3,
P. Martin van Hagen1,2,3 and Willem A. Dik1
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inflammatory mediator synthesis by fibroblasts, thereby contributing to wound healing 
and tissue remodeling but also fibrosis 22-37. Histamine effects can be mediated through 
four types of G-protein coupled histamine receptors; HRH1 to HRH4 38 but differences 
in specific histamine receptor involvement may exist between fibroblasts from different 
anatomical regions 36, 39. Although orbital fibroblast activation is at the heart of GO 
pathogenesis and there is data to implicate that mast cell-derived factors contribute to 
this 40, the contribution of histamine to GO, especially with regard to orbital fibroblast 
activation has not been examined so far. 
The purpose of the present study was to evaluate the effect of histamine on the 
production of cytokines (IL-6, IL-8, CCL2, CCL5, CCL7, CXCL10 and CXCL11) 
previously implicated in GO as well as hyaluronan by orbital fibroblasts. Histamine 
receptor subtype involvement and NF-NB signaling was further investigated using 
pharmacological inhibitors.  
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Fig. 5. The effect of NF-NB inhibition on histamine-induced cytokine production by 
orbital fibroblasts. 
Orbital fibroblasts (GO n = 4, controls n = 3) were stimulated with histamine (5 mM) in 
the presence or absence of the IKK2 inhibitor SC-514 (concentration range 1-10 M) for 
48 hours. Culture supernatants were analyzed for IL-6 (A), IL-8 (B) and CCL2 (C). Each 
bar represents the mean value and the SEM. Data were analyzed using ANOVA 
followed by Mann Whitney U test. * and ** indicate p-value of <0.05 and <0.01, 
respectively.  
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including ATP release, Ca2+ mobilization, cGMP, p38, ERK and JNK 36, 38, 53, 57. Also the 
inability of  histamine to stimulate the production of CCL5, CCL7, CXCL10 and CXCL11 
indicates that histamine-induced HRH1 activation in orbital fibroblasts is not sufficiently 
activating signal pathways and transcriptional machinery required for the production of 
these chemokines, which requires for instance the transcription factor interferon 
regulatory factor (IRF)-3 58.  
 Hyaluronan production by orbital fibroblasts plays an important role GO 4, 40. 
Histamine did enhance HAS1 and HAS3 mRNA expression by orbital fibroblasts, yet did 
not result in increased hyaluronan production. This latter is most likely not related to 
increased hyaluronan degradation as histamine did not enhance mRNA levels for four 
main hyaluronidases in orbital fibroblasts. Histamine did however not enhance the 
expression level of HAS2, which is considered to represent the main HAS isoform 
involved in hyaluronan synthesis by orbital fibroblasts in GO 40, 59. 
 In conclusion our data indicate that the mast cell mediator histamine can induce 
the production of NF-ț% FRQWUROOHG-cytokines by orbital fibroblasts and as such can 
contribute to the pathologic orbital environment in GO. Our findings are relevant in 
relation to the improvement of tearing, itching and dryness of the eyes observed in a 
small cohort of GO patients treated with the HRH1 antagonist cetirizine in combination 
with the leukotriene receptor antagonist montelukast 60. Our data are therefore in 
support of the hypothesis that orbital fibroblast activation by mast cell-derived products 
is an important mechanism in the pathogenesis of GO and that mast cells, their 
mediators and downstream receptors might represent therapeutic targets in GO.  
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Abstract
Introduction
Systemic  sclerosis  (SSc)  is  an  often  therapy  refractory  autoimmune  disease
characterized by excessive collagen deposition. In this study we examined the effect 
of imatinib mesylate (IM) in the treatment of SSc and determined whether the effect
could be predicted using markers of collagen synthesis and Interferon type I induced
gene expression, the so-called IFN type I signature.
Methods
10 previously therapy refractory SSc patients were treated with IM 400 mg orally.
Response was assessed by using overall SSc activity score and Modified Rodnan
Skin Score (MRSS). Serum N-terminal propeptide of type III collagen (PIIINP) was
used as a biomarker for collagen synthesis. Interferon (IFN) type I signature expression
was used as a biomarker for disease activity.
Results
Only one patient showed a decrease of 2 points in overall SSc activity score. Two
patients had a clinically relevant decrease in MRSS. The two patients with a skin
response had significantly higher PIIINP levels at baseline and were the only ones to
show an IFN-type I signature.
Discussion
IM 400 mg daily has limited effect in SSc. The patients that did respond with softening
of the skin had significantly higher markers of collagen synthesis and showed a
IFN-type I signature. The latter results might help in selecting patients that are
responsive to therapy.
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Introduction 
Systemic sclerosis (SSc) is a difficult to treat, severely debilitating, 
autoimmune disease characterized by vasculopathy, immune activation and fibrosis 
of the skin and internal organs. Imatinib mesylate (IM), is used as a treatment for 
therapy-refractory SSc with high variability in therapeutic outcomes ranging from 
ineffective/toxic responses to extremely encouraging clinical improvement.1 This high 
variability in treatment outcomes stresses the need for a biomarker identifying SSc 
patients likely to respond to IM treatment.  
We conducted a study to determine the effect of IM in a group of patients with 
SSc who had failed on previous immunosuppressive drug treatment. Furthermore we 
examined whether the effect of treatment could be predicted using biomarkers of 
collagen synthesis and disease activity. Serum N-terminal propeptide of type III 
collagen (PIIINP) that has been reported increased in the skin and serum of SSc 
patients was used as a biomarker for collagen synthesis.2 Interferon type I induced 
gene expression in monocytes, the IFN type I signature, has been shown to correlate 
with disease activity in various autoimmune diseases including SSc and was used as 
a biomarker for disease activity.3 
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Material and methods: 
We performed an open label study in which we intended to treat 10 SSc 
patients with IM 400mg/day for one year. All patients included in this open-label trial 
met the American College of Rheumatology criteria for SSc.4 Patients (over 18 years 
of age) had to be refractory to therapy with either cyclophosphamide, Methotrexate 
or Mycophenolic acid. Adequate end organ function, defined as: total bilirubin <1.5 x 
ULN, SGOT and SGPT < 2.5 x ULN (or <5 x ULN if hepatic disease involvement is 
present), creatinine < 1.5 x ULN, ANC >1.5 x 109/L, platelets > 100 x 109/L, was 
required. All patients gave written informed consent. The Medical Ethics committee 
of Erasmus MC approved the study.  
The initial primary endpoint for response to IM was defined as a significant 
decrease in SSc mean Modified Rodnan Skin Score (MRSS).5 A 10-point reduction 
or normalisation in Rodnan skin score at 12 months was regarded a major response. 
Assuming a standard deviation in the difference between the two measurements of 
10, this study has a power of 0.8 to detect a 10-point difference with a significance 
level of 0.05. Furthermore absence of progression in pulmonary, skin and renal 
disease after one year (all required) was considered necessary for a major response.  
However, as three patients included in the study had a Rodnan skin score at 
baseline below 10 the primary endpoint was redefined as a reduction of at least 2 
points in overall SSc severity score using the Medsger Disease Severity Scale.6 
Secondary efficacy parameters were total lung capacity (TLC) and diffusing capacity 
for carbon monoxide (DLCO) and Modified Rodnan skin score.  
In addition to these parameters, blood and serum were collected prior to IM 
treatment and at 3, 6, 9 en 12 months of treatment. Interferon type I signature 
expression and B-cell activating factor (BAFF) mRNA expression were determined in 
monocytes as described previously7. PIIINP was measured using the UniQ ® PIIINP 
RIA (Orion Diagnostica, Espoo, Finland). Assay was performed following the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV 
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Results: 
Patient characteristics are summarized in Table 1. Disease activity as 
measured by overall SSc severity score varied between 4 and 11. Two patients 
stopped treatment within 3 months as they did not notice any improvement and 
where no longer motivated to continue. In terms of the redefined primary endpoint 
only one patient showed a response. Two other patients had a one-point reduction in 
overall SSc severity. None of the patients had an increase in overall severity score. 
One of the patients with a one-point decrease in SSc severity score showed a 
reduction of more than 10 points on MRSS. The other patient with a one-point 
reduction had substantial improvement in gastrointestinal function. One additional 
patient had a decrease of 8 points on MRSS after one year. This patient also 
showed a remarkable improvement in pulmonary function (TLC baseline: 77% of 
predicted, end of study: 92%; Diffusion capacity baseline: 74%, end of study: 88%). 
We isolated monocytes from 8 of the SSc patients included who completed 
the study and analysed the IFN type I signature expression. Only the monocytes 
from the 2 patients who showed a decrease in MRSS displayed a positive IFN type I 
signature at baseline (Figure 1A). The IFN type I signature remained the same 
during IM treatment (Figure 1A-B).  
Previously, we found B cell activating factor (BAFF) mRNA to strongly 
FRUUHODWH ZLWK WKH SUHVHQFH RI WKH ,)1 W\SH , VLJQDWXUH LQ 6M|JUHQ¶V V\QGURPH
patients7 and BAFF serum levels were found to correlate with the extent of SSc skin 
fibrosis.8 We therefore assessed BAFF mRNA expression in monocytes from the 
SSc patients in our study. The two skin responders showed the highest levels of 
BAFF mRNA at baseline, which decreased significantly upon IM treatment (Figure 
1C-D).  
Baseline and follow-up PIIINP levels were assessed in serum of 7 of the SSc 
patients. The two skin responders showed much higher baseline PIIINP levels than 
the other SSc patients, decreasing drastically upon 6 months of IM treatment (Figure 
1E).  
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*UDYHV¶GLVHDVH*'PD\EHFRPSOLFDWHGE\*UDYHV¶RSKWKDOPRSDWK\*2DFRQGLWLRQ
that remains difficult to treat in a significant number of patients, as many of these patients 
do not respond to currently available therapeutic options. Treatment options for GO 
available so far are limited, which is most likely related to the complex pathophysiology of 
the disease. Currently, the most common and effective treatment for active moderate-to-
severe and sight-threatening GO is (high dose) intravenous glucocorticoids 1. However, 
glucocorticoid treatment shows high success rates only if it is introduced in an active 
inflammatory phase of the disease 2, 3. It has been recognized that up to 40% of patients 
do not respond to the currently used immunosuppressive treatment with glucocorticoids 
4, and orbital decompression surgery is applied when patients fail to respond to 
glucocorticoids or for rehabilitating purposes 2, 3. This clearly indicates the need for 
improved insight into the pathophysiological processes involved in GO as this will help 
to facilitate development of novel therapeutic interventions. Currently, orbital fibroblast 
activation followed by excessive proliferation, hyaluronan and inflammatory mediator 
production and differentiation of orbital fibroblasts into adipocytes and pro-fibrotic 
myofibroblasts are considered central processes in the (immune) pathogenesis of GO 5. 
Consequently, it has been hypothesized that therapies targeting orbital fibroblast activity 
could be promising treatment options in GO 6. PDGF-BB was previously found to be 
elevated in orbital tissues from GO patients and it plays an important role in orbital 
fibroblast activation by inducing inflammatory and tissue remodeling processes. Along 
this line the tyrosine kinase inhibitors (TKIs) imatinib mesylate and nilotinib that target the 
platelet derived growth factor (PDGF)-receptor (PDGF-R) have been proposed as 
treatment options for GO 7. However, for optimal clinical application of such TKIs in GO a 
better understanding of the orbital fibroblast activating properties of PDGF along with that 
of other growth factors is required. Alternatively, other ways of interfering with receptor 
tyrosine kinase activation can be thought of, for example with small molecules that target 
downstream signaling pathways such as PI3K and MAPK 8, 9.  Moreover, additional 
factors such as mediators produced by mast cells that might be able to activate orbital 
fibroblasts need to be identified as they may represent therapeutic targets as well, either 
alone or in combination with other mediators. The studies performed in this thesis 
generated new insights into the complex biological processes involved in GO. This could 
be of relevance for the development of novel therapeutic interventions and will be further 
discussed hereunder. In addition, important directions for future research are indicated. 
 
 
NOVEL INSIGHTS IN THE PATHOGENESIS OF *5$9(6¶23+7+$/02/2*< 
 
 
In GO the clinical symptoms are driven by three main pathologic features: 1) 
inflammation, 2) increased accumulation of extracellular matrix components (ECM) 
(mostly hyaluronan), and 3) enhanced adipogenesis 5. These dynamic processes all 
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occur within the context of the space limited orbital cavity, resulting in typical 
clinical features, including upper eye lid retraction, edema, erythema of the 
periorbital tissues and conjunctivae, and proptosis 10, 11. PDGF-BB was previously 
found to be elevated in orbital tissues from GO patients, at all stages of disease, 
suggestive for a role in inflammation as well as tissue remodeling 7. In support of 
this it was demonstrated that PDGF-BB: 
1) stimulates orbital fibroblasts to produce chemokines and cytokines 
involved in recruitment, activation and differentiation of immune cells, 
including monocytes, macrophages, T lymphocytes and B lymphocytes 12  
2) stimulates orbital fibroblast proliferation and hyaluronan production, 
processes that will largely contribute to tissue volume expansion 7, 13 
3) enhances the expression of thyroid stimulating hormone (TSH) receptors 
(TSHR) on orbital fibroblasts, which increases susceptibility of orbital 
fibroblasts to activation by TSHR stimulatory autoantibodies resulting in 
increased production of cytokines and hyaluronan 14. 
These data clearly link PDGF-BB and the autoimmune inflammatory process 
involved in GO. However, another major process involved in orbital tissue volume 
expansion in GO is the differentiation of orbital fibroblasts into adipocytes 10, 11. 
Several mediators have been proposed to enhance adipogenesis by orbital 
fibroblasts in GO, including interleukin (IL)-1E, IL-6, prostaglandin D2 (PGD2) and 
TSHR stimulatory autoantibodies 15-19. Studies in this thesis demonstrated that 
PDGF-BB enhanced adipogenesis by orbital fibroblasts that were cultured in a pro -
adipogenic environment (Chapter 4). This effect was not mediated via induction of 
autocrine IL-6 signaling. It is also unlikely that IL-1E production and signaling was 
involved as PDGF-BB does not stimulate IL-1E production by orbital fibroblasts 12. 
However, so far it cannot be excluded that other factors induced by PDGF-BB are 
involved in this. Remarkably, for other cell types, including adipose-derived stem 
cells and mesenchymal stromal cells, PDGF-BB has been identified as anti-
adipogenic factor, which involved activation of signaling molecules such as 
extracellular signal-regulated kinase (ERK), phosphoinositide 3-kinase (PI3K) and 
protein kinase C (PKC)D/G 20-23. On the other hand, PDGF also activates the 
signaling molecule c-Abl, which is a tyrosine kinase that was recently identified to 
be indispensable for adipocyte differentiation by murine 3T3-L1 preadipocytes 24-
26. Although c-Abl activation by PDGF-BB in orbital fibroblasts has not been 
examined so far, it cannot be excluded that PDGF-BB-driven adipocyte 
differentiation by orbital fibroblasts involves c-Abl activity.  
 
What exactly creates the pro-adipogenic environment in orbital tissue from 
GO patients is still far from clear, but there are indications that mostly Thy1- 
orbital fibroblasts differentiate into adipocytes. Studies exploring the effects of 
PDGF-BB on adipogenesis by Thy1- and Thy1+ orbital fibroblasts would therefore 
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be of interest. A recent study by Li et al. demonstrated that Thy1- orbital 
fibroblasts cultured under pathological pressure in a three-dimensional collagen matrix 
differentiate into adipocytes 27. This in vitro model mimics the increased mechanical 
pressure that orbital fibroblasts from GO patients encounter within the context of the 
noncompliant and space limited orbital cavity, which thus provides pro-adipogenic 
signals. It would be of interest to examine the contribution of PDGF-BB in this model.  
Fibrocytes are bone marrow derived cells that can be considered as connective 
tissue progenitors that circulate in the blood and infiltrate damaged tissue where they 
contribute to inflammation, tissue remodeling and fibrosis 28-30. In GO, fibrocytes were 
found to infiltrate the orbital tissue where they further contribute to the heterogeneity of 
the orbital fibroblast pool 31. Fibrocytes were demonstrated to express TSHR and to 
spontaneously differentiate into adipocytes which was associated with a further increase 
in TSHR expression 31. Fibrocytes express PDGF-R and the PDGF-5ȕ-PDGF-BB axis 
has been proposed to contribute to the recruitment of fibrocytes into tissue 32. Whether 
PDGF-BB, or other PDGF isoforms, also drive adipogenesis by fibrocytes has not been 
explored so far but such studies would be of relevance to further delineate GO 
pathogenesis.  
 Nevertheless, the data presented in this thesis demonstrate that PDGF-BB has the 
ability to stimulate adipogenesis by a heterogeneous pool of orbital fibroblasts. This, 
along with the already observed effects of PDGF-BB on proliferation, hyaluronan, 
cytokine/chemokine production and TSHR expression by orbital fibroblasts indicates that 
PDGF-BB may represent a key factor in the pathogenesis of GO. This notion is further 
strengthened by the observations from chapter 5 where the actions of PDGF-BB were 
explored in combination with other growth factors implicated in GO.  
 
Basic fibroblast growth factor (bFGF) is a growth factor that is implicated in organ 
fibrosis, especially via the stimulation of proliferation and ECM production by fibroblasts 
33-37. In orbital tissues from GO patients, elevated bFGF expression was observed and 
immunohistochemical studies identified orbital fibroblasts, adipocytes and endothelial 
cells as producing sources 38, 39. Also elevated serum bFGF levels have been observed in 
GO patients 40, but the contribution of bFGF to orbital fibroblast activation has been 
hardly studied. The study in chapter 5 demonstrated that bFGF synergistically enhanced 
the capacity of PDGF-BB to stimulate hyaluronan and IL-6 production by orbital 
fibroblasts. Importantly, bFGF alone did not stimulate IL-6 production by orbital 
fibroblasts, which underlines the importance of studying combined effects of growth 
factors in GO. In other cell types synergistic effects of PDGF and bFGF were observed as 
well and depended on prolonged activation of signaling molecules, enhanced growth 
factor receptor expression and autocrine release of additional growth factors. In human 
smooth muscle cells autocrine bFGF signaling enhanced and prolonged ERK activation 
in PDGF-BB-induced cell proliferation 41. In addition, induction of PDGF-R expression 
upon bFGF stimulation and the induction of FGF-R1 expression upon PDGF-BB 
stimulation have been observed in various cell types such as vascular smooth muscle 
cells, endothelial cells, pericytes and foreskin fibroblasts 42-44. We did not observe an 
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effect of bFGF on PDGF-5ĮDQG3'*)-5ȕP51$H[SUHVVLRQQRUDQHIIHFWRI3'*)-BB 
on FGF-R1 mRNA expression in orbital fibroblasts. Activated FGF-R can also 
transactivate the PDGF-R 45. It is however unlikely that transactivation of PDGF-R 
contributed to the synergistic enhancement observed in our studies as the TKI dasatinib, 
that inhibits the tyrosine kinase activity of the PDGF-R but not FGF-R, had no effect on 
bFGF-induced hyaluronan and IL-6 production by orbital fibroblasts (Chapter 5). Although 
usage of a PDGFB knockout orbital fibroblast model would have strengthened the study 
presented in chapter 6 it is still feasible to hypothesize that the synergistic effect of 
bFGF and PDGF-BB on hyaluronan and IL-6 production involves prolonged autocrine 
PDGF-BB signaling (Chapter 6).  
The data from chapter 5 also demonstrated that bFGF did not synergistically 
enhance orbital fibroblast proliferation induced by PDGF-BB but only had an additive 
effect on this. This stresses the importance of studying combined effects of growth factors 
on several aspects of orbital fibroblast activation in GO, as different outcomes can be 
expected. Further studies that explore the effects of growth factors alone or combinations 
thereof are therefore warranted.  
 
Transforming growth factor (TGF)-ȕ1 was previously found to be elevated in GO 
orbital tissue and stimulated hyaluronan production by orbital fibroblasts. Moreover, it was 
demonstrated that co-stimulation of orbital fibroblasts with TGF-ȕ1 and PDGF-BB showed 
an additive effect of TGF-ȕ1 to PDGF-BB on hyaluronan production 7. However, the effect 
of TGF-E1 on adipogenesis in orbital fibroblasts remains controversial 46, 47. A preliminary 
study exploring the effect of TGF-ȕ1 alone and in combination with PDGF-BB on 
adipogenesis was therefore performed. This revealed that TGF-E1 did not affect 
adipogenesis in orbital fibroblast cultures when compared to differentiation medium 
alone (Figure 1 and 2A), nor did it induce expression of the adipocyte predominant 
transcription factor peroxisome proliferator-activated receptor gamma (PPARȖ) by 
orbital fibroblasts (Figure 2B). Remarkably, TGF-E1 significantly inhibited PDGF-BB-
induced adipogenesis (Figure 2). In line with this,  TGF-E1 is known to downregulate 
TSHR expression by orbital fibroblasts 47, while PDGF-BB enhances TSHR expression, 
which is associated with adipogenesis of orbital fibroblasts 14, 48. These data are thus 
clearly in support of opposing effects of TGF-ȕ1 and PDGF-BB on adipogenesis by orbital 
fibroblasts. It is currently unknown how TGF-E1 inhibits the pro-adipogenic effect of 
PDGF-BB, but activation of SMAD family member 3 (SMAD3) might be involved as 
previous studies demonstrated inhibition of adipogenesis by TGF-E1 stimulated SMAD3 
activity 49.  
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Figure 1. Oil-Red-O staining on orbital fibroblasts.
Orbital fibroblasts were cultured in nondifferentiation medium (A), adipocyte differentiation
medium (B), adipocyte differentiation medium in the presence of PDGF-BB (50 ng/ml) (C),
adipocyte differentiation medium in the presence of TGF-     (10 ng/ml) (D) and adipocyte
differentiation medium in the presence of PDGF-BB and TGF-    (E). Oil-Red-O staining was
performed after 14 days of differentiation. Results from a representative orbital fibroblast
culture are displayed.
173 
Chapter 9General discussion
9
87A_BW Virakul stand.job_Press Sheet Size 17x24 cm
Figure 2. Quantification of adipogenesis in orbital fibroblasts.
(A) Oil-Red-O staining was quantified in eluate after 14 days of differentiation of orbital
fibroblasts from controls (n=3) and GO patients (n=3) using a spectrophotometer at 490 nm.
(B) Expression of PPAR-Ȗ mRNA was determined by RQ-PCR and normalized to the control
gene ABL in orbital fibroblasts from controls (n=3) and GO patients (n=3) after 14 days of
adipocyte differentiation. Each dot represents the orbital fibroblast strain from one individual and
horizontal bars represent the mean values within a group. Data were analyzed using ANOVA
followed by Mann Whitney U test.
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POTENTIAL TREATMENT STRATEGIES FOR GRAV(6¶ OPHTHALMOPATHY 
 
 
 Imatinib mesylate versus Dasatinib 
 
Based on our previous findings on the important role of PDGF in the pathogenesis of 
GO, TKIs imatinib mesylate and nilotinib that target the PDGF-R have been proposed as 
potential treatment options for GO 7. However, the use of imatinib mesylate, and 
especially nilotinib, is associated with various side effects such as peri-orbital edema, 
peripheral arterial occlusive disease and cerebrovascular events when used in the 
treatment of chronic myeloid leukemia (CML) 82, 83. As a result, imatinib mesylate and 
nilotinib may not represent preferable treatment options for GO, at least not when given in 
dosages comparable to those used to treat CML patients. Nevertheless, targeting the 
important pathogenic PDGF pathway in GO with other clinically available TKIs could still 
be considered for therapy-refractory patients or patients with sight-threatening disease. 
Dasatinib, a second-generation TKI, is a less specific TKI than imatinib mesylate and 
nilotinib, but it displays a considerably higher inhibitory potency for both PDGF-5ĮDQG
PDGF-5ȕ FKDLQV ZKHQ FRPSDUHG WR LPDWLQLE PHV\ODWH DQG QLORWLQib 84. In addition, 
dasatinib is associated with fewer side effects than imatinib mesylate in the treatment of 
CML 85, 86. Moreover, in pre-clinical models of fibrotic diseases like systemic sclerosis, 
pulmonary fibrosis and cardiac fibrosis, dasatinib significantly reduced disease activity as 
demonstrated by the reduction in dermal thickness and lung fibrosis and the improvement 
in ventricular function 87-89. These studies underline the potential clinical implications of 
dasatinib in fibrotic diseases. To provide a basis for the potential future introduction of 
dasatinib in the treatment of GO, the in vitro, ex vivo and clinical effects of dasatinib were 
investigated in this thesis and will be further discussed hereunder. 
In chapters 3 and 4 in vitro and ex vivo studies are described, showing that dasatinib 
effectively inhibits PDGF-BB-induced proliferation, cytokine (CCL2, IL-6, IL-8) and 
hyaluronan production by orbital fibroblasts. Moreover, dasatinib also effectively inhibited 
adipogenesis and cytokine and hyaluronan production by whole orbital tissues derived 
from active GO patients 90, 91. Interestingly, when compared to imatinib mesylate, 
significantly lower dosages of dasatinib were needed to inhibit PDGF-BB induced 
proliferation, cytokine and hyaluronan production by orbital fibroblasts 91. This difference 
in effects could potentially be explained by the higher inhibitory potency of dasatinib for 
PDGF-RD and PDGF-RE 8 4 . When these effects of dasatinib could be extrapolated to 
the in vivo situation, dasatinib could be a promising drug in the treatment of GO, as 
fewer side effects could be expected with the use of lower dosages, when compared to 
imatinib mesylate. Although dasatinib could be an interesting therapeutic option in GO, it 
should be taken into account that in other studies it was described that dasatinib 
stimulated adipogenesis in human bone marrow-derived mesenchymal stromal cells 92. 
In GO, orbital fibroblasts with overlapping features of mesenchymal stem cells may be 
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Figure 5. Effects  of  dasatinib  on  gene  expression  in  whole  orbital tissue from a
patient with severe, sight-threatening GO.
Orbital tissues were put in culture in the presence or absence of dasatinib. mRNA expression
levels from the orbital tissues were determined by RQ-PCR  after  24  hours,  normalized  to
the control  gene ABL  and  expressed  relative  to  the  untreated  tissue.  Horizontal bars
represent  the  mean  values,  error  bars  indicate  the  standard error of the mean. 100%
represents a comparable expression compared to untreated orbital tissue and other values
represent percentages of expression compared to the untreated tissue.
 Based on these ex vivo data obtained from whole tissue cultures from the GO
patient presented above and the fact that the  patient  still  suffered  from  very  severe,
therapy-refractory  GO which  required  systemic  treatment  after  debulking  surgery in
order to prevent further expansion of orbital tissue, we decided,  after obtaining  written
informed consent by the patient and approval by our institutional review board,  to  start
treatment with dasatinib. Initially, a dose of 50 mg once daily was prescribed in order to
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evaluate tolerability and side effects. After 4 weeks of treatment, the dosage was 
increased up to 100 mg once daily. Clinical evaluation after 6 weeks revealed a 
significant reduction of the CAS from 6/7 to 4/7 (Figure 6). Interestingly, her myxedema 
totally resolved over this period. TSHR autoantibody levels remained high with 98.4 IU/l, 
while thyroid function restored (fT4 13.9 pmol/ml and TSH 3.6 mU/l) (Figure 6). Because 
of significant clinical improvement and absence of side effects, treatment with dasatinib 
once daily 100 mg was continued. However, after 4 months of medical treatment the 
patient presented to the ophthalmologist with acute, sight-threatening progressive GO, 
for which acute decompression surgery was warranted. Treatment with dasatinib was 
terminated at that moment. Remarkably, we did not see any recurrence of her pretibial 
myxedema. After debulking surgery, oral glucocorticoid treatment was started in a 
tapering regimen. Her clinical condition remained stable and glucocorticoid treatment 
was terminated after 3 months. No need for additional systemic treatment was needed 
till date. 
In conclusion, our ex vivo and clinical data on dasatinib support the potential 
clinical implication of the TKI dasatinib in patients with very severe and/or sight-
threatening GO, in which conventional therapies are ineffective. There are however 
some limitations to our study. After initial improvement of GO, 4 months after start of 
treatment, there was significant progressive disease requiring acute decompression 
surgery. Several reasons for these findings could be hypothesized. First of all, it has 
been previously described that dasatinib stimulates adipogenesis in a cell-type specific 
manner 92. Although we did not find such an effect of dasatinib on orbital fibroblasts in 
vitro, it cannot be ruled out that activation of mesenchymal stem cells-like orbital 
fibroblasts in the orbital tissue 93, 94 resulted in increased adipogenesis in our patient 
after several months of treatment, resulting in progressive GO. The initial response could 
then assign to the interference of dasatinib with the PDGF-signaling pathway. On the 
other hand, dasatinib is a rather selective TKI which does not target the FGF-R and as 
described in chapter 5 bFGF may significantly contribute to the pathogenesis of GO and 
may therefore be a target for therapy as well. Therefore, studies on novel TKIs, with a 
broader range of action should reveal whether these compounds could be of more 
interest as potential therapeutic options in GO. We also found a striking difference in the 
response to dasatinib in the patient between the orbital region and the skin (pretibial 
myxedema). It could be speculated that concentration differences between the orbital 
tissue and skin from the lower leg might be responsible for these site specific differences 
in effects of dasatinib when systemically administered. Current studies are evaluating 
potential differences in concentrations of dasatinib between the orbital tissue and skin 
lesions obtained from the patient described.  
Although our initial findings on the effects of dasatinib in GO were promising, 
there is still need for broader therapeutic approaches in GO, as in our patient after 4 
months of therapy progressive disease activity was experienced. 
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Figure 6. Clinical features of a patient with severe GO before and after 6 weeks of 
dasatinib treatment.  The patient presented with GO with CAS 6/7 (upper left picture) and 
pre-tibial myxedema (lower left picture). After 6 weeks of dasatinib treatment CAS had 
reduced from 6/7 to 4/7 (upper right picture) and pre-tibial myxedema completely 
resolved (lower right picture). 
 
 
 Nintedanib 
 
In studies described in chapters 5 and 6 we demonstrated that also other signaling 
pathways than the PDGF-cascade targeted by dasatinib could be of importance in the 
pathogenesis of GO, necessitating the exploration of other TKIs in the treatment of GO. 
bFGF signaling was found to induce orbital fibroblast proliferation and hyaluronan 
Figure 6. Clinical features of a patient with severe GO before and after 6 weeks of
dasatinib treatment.
The patient presented with GO with CAS 6/7 (upper left picture) and pre-tibial myxedema
(lower left picture). After 6 weeks of dasatinib treatment CAS had reduced from 6/7 to 4/7
(upper right picture) and pre-tibial myxedema completely resolved (lower right picture).
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production by orbital fibroblasts. Moreover, co-stimulation with PDGF-BB and bFGF 
resulted in the additive/synergistic induction of orbital fibroblast activation which 
highlights the importance of evaluating TKI that might block both PDGF and bFGF 
signaling pathways. Nintedanib, a TKI that targets PDGFRs, FGFRs and VEGFRs 96, 97, 
effectively blocked the additive/synergistic effects of PDGF-BB and bFGF on orbital 
fibroblasts while dasatinib, which targets only PDGFRs, only blocked the PDGF-BB 
effect (Chapter 5). These data indicate that multiple receptor tyrosine kinase (RTK) 
directed therapy could be promising in reducing excessive orbital fibroblast activity 
present in GO. In previous studies in fibrotic diseases it was demonstrated that 
nintedanib was very effective. Treatment with nintedanib significantly improved outcome 
in the aggressive pulmonary fibro-proliferative disease idiopathic pulmonary fibrosis (IPF) 
97. Remarkably, these data showed that nintedanib was able to reverse established 
fibrosis. In pre-clinical models for systemic sclerosis (SSc), nintedanib was found to inhibit 
fibroblast activation and to exert potent anti-fibrotic effects as well 98. These last results have 
led to the recent start of a phase 3 clinical trial with nintedanib in patients with SSc related 
lung fibrosis (ClinicalTrials.gov NCT02597933). Moreover, the use of nintedanib was 
associated with minor side effects such as diarrhea and nausea when compared to other 
TKIs such as imatinib mesylate, nilotinib and dasatinib 83, 96, 97. As a result, it would be of 
interest to investigate the effects of nintedanib in established GO. In our in vitro and ex 
vivo models nintedanib was found to effectively inhibit fibroblast proliferation and 
activation in GO. There could be however some drawbacks on the use of nintedanib in 
GO. The systemic blocking of FGF-R could interfere with various other pathways as FGF-
Rs are expressed by fibroblasts, epithelial, mesenchymal and inflammatory cells involved 
in tissue repair. Targeting FGF-Rs could therefore interfere with processes essential after 
tissue injury 99. In addition, FGF21 and FGFR1 have an important role in glucose intake 
100-104 while FGFR4 is expressed by hepatocytes and mainly controls bile acid synthesis 
105. Collectively, it cannot be excluded that long-term nintedanib treatment might cause 
undesirable effects in response to tissue injury and might cause hypercholesterolemia, 
hyperbilirubinemia and type-2 diabetes 102-105. Future safety and efficacy studies are 
needed to address these topics in more detail. 
 
 Other therapeutic interventions 
 
Chapter 8 describes the therapeutic effects of the TKI imatinib mesylate in a number 
of patients with SSc. SSc is a debilitating autoimmune disease with significant morbidity 
and mortality. It is characterized by a fibroproliferative vasculopathy, excessive 
production of ECM and an aberrant autoimmune activation resulting in skin and visceral 
organ fibrosis 106. The underlying pathophysiologic mechanisms remain elusive and 
effective therapeutic options are limited. Progressive fibrosis is a hallmark of this disease 
and SSc could be used as a disease model for other diseases in which fibrosis is 
involved. Introduction of TKI treatment in SSc was based on several pre-clinical 
studies that showed beneficial effects from imatinib mesylate in targeting dermal 
fibroblast activity 107, 108. In a recent report by Bournia et al. it was also demonstrated 
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that imatinib mesylate could be considered an individualized treatment approach in 
severe SSc 109. 
In chapter 8 we describe a number of SSc patients who had failed on previous 
immunosuppressive drugs that were subsequently treated with imatinib mesylate. None 
of the patients deteriorated, and two patients showed a reduction in modified Rodnan skin 
score (mRSS). Biomarkers predicting which patients could respond to imatinib mesylate 
treatment were identified. Data in chapter 8 showed that patients who were positive for 
interferon (IFN) type I signature with high B-cell activating factor (BAFF) and high 
procollagen III N-terminal pro-peptide (PIIINP) levels responded to imatinib mesylate 
treatment. Even though the data suggested that IFN type I signature, BAFF and PIIINP 
level could predict the patients who are susceptible for imatinib mesylate treatment, and 
selected patients could thus benefit from such treatment, other alternative treatment 
regimens for SSc are needed. In previous, preliminary, studies we have demonstrated 
that fibroblast proliferation could be influenced by somatostatin (SS) analogues 
(unpublished results). 
 
SS is a 14-amino acid neuropeptide with a variety of actions throughout the human 
body. Most of these actions are mainly inhibitory like, for instance on hormone secretion 
by the pituitary gland, thyroid gland and pancreas 110, 111. Previous studies have shown 
that SS analogues also exert effects on various immune cells, where it influences 
chemotaxis, apoptosis and cytokine secretion 112, 113. In addition, SS inhibits tumour 
growth, especially in neuroendocrine tumours 114, 115.  
In order to evaluate the effects of SS on fibroblast activation and proliferation in SSc, 
as a model for fibrotic disease, 3 skin biopsies from affected skin were obtained from 3 
patients with active and therapy-refractory SSc associated skin disease. Written informed 
consent and approval by our institutional review board were obtained. One whole tissue 
sample was cultured overnight in DMEM 1% FCS in the presence of imatinib mesylate 
(2.5 g/ml), the second tissue sample was cultured in the presence of SS (10-8 M), and 
the third sample was put in culture without any treatment, serving as internal control. 
mRNA was extracted, reversed transcribed into cDNA, and gene expression levels were 
determined by RQ-PCR. In two out of three SSc patient tissues imatinib mesylate 
reduced IL6, CCL2, TNF and IL10 mRNA expression levels while the expression levels of 
TGF-E1 anGFROODJHQW\SHĮCol1Į1) were not affected by imatinib mesylate in all 
tissues (Figure 7A). Despite the fact that due to the small sized skin biopsies taken in this 
study, no further studies could be performed. It would be interesting to investigate the IFN 
type I signature in these biopsies and compare the results to the findings obtained in 
chapter 8. In one out of three SSc  patient skin biopsies it was found that SS reduced IL6, 
IL8, TNF and IL10 mRNA expression levels while the expression levels of TGF-E1 and 
Col1Į1 were not affected by SS in all tissues (Figure 7B). As TGF-E1 which can stimulate 
collagen production by skin fibroblasts and both TGF-E1 and Col1Į1 mRNA expression 
levels were not affected by both imatinib mesylate and SS 116, 117, these data suggest 
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that imatinib mesylate and SS might primarily target the inflammatory response by 
reducing pro-inflammatory cytokine production rather directly target on the process of 
excessive production of ECM. Further studies are needed to elucidate the effects of SS 
and its analogues in fibrotic diseases, like SSc. Moreover, combined treatment regimens, 
consisting of TKIs and SS analogues, could show additive or synergistic effects in 
inhibition of fibroblast activation and/or proliferation. 
 
In one study in GO it was demonstrated that SS receptor 1 (SSTR1) expression was 
upregulated in orbital adipose tissue when compared to control tissue 118. However, 
treatment of GO patients with SS or one of its analogues, octreotide and lanreotide which 
targets SSTR2 119, did not show clinical improvement in GO 120-123. These data suggested 
that SS and its analogues might be able to target SSTR2 expressed by primary orbital 
fibroblasts 124 and SSTR2 expressed by macrophages and dendritic cells 125, but SS and 
its analogues might not be able to reduce the overall orbital activation in GO. SS and its 
analogues also induce phosphatase activity which is associated with MAP kinase, AP-1 
and NF-NB dephosphorylation 126, 127 which are also downstream signaling molecules of 
PDGF-Rs and FGF-Rs 8, 128. However, to our knowledge, it is unknown whether this 
phosphatase activity induced by SS had any inhibitory effect on RTK such as PDGF-Rs 
and FGF-Rs. Combining SS with TKI in the treatment of GO might be beneficial in 
inhibiting RTK activity involved with orbital fibroblast activation in GO. 
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Figure 7 . Effects of imatinib mesylate and somatostatin on gene expression
profiles in skin biopsies from 3 SSc patients.
Skin biopsies from 3 patients with active and therapy-refractory SSc associated skin disease
were obtained and put in culture in the presence or absence of (A) imatinib mesylate
(2.5 ȝg/ml) or (B) SS (10-8 M) for 24 hours. Gene expression levels were determined by
RQ-PCR, normalized to the control gene ABL. Each line represents the response of tissue
from an individual patient.
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 As already suggested, leukotriene receptor antagonist montelukast in combination 
with the HRH1 antagonist cetirizine would be of interest to investigate in a larger group 
of patients. In addition, combined treatment of phosphatase activity of SS with TKI in 
targeting RTK activity might show more beneficial effects in disease activity than 
introducing SS or TKI alone. As has been shown in the murine pulmonary fibrosis 
model, combinations of TKIs could be considered in GO, to target multiple pathways. 
Moreover,  prostaglandin F2-alpha 3*)Į VLJQLILFDQWO\ UHGXFHG SUROLIHUDWLRQ DQG
adipogenesis in orbital fibroblasts from GO patients 1497KHXVHRI3*)Į eye drops in 
targeting proptosis (ClinicalTrials.gov NCT02059655) in combination with the TKIs 
dasatinib or nintedanib would be of interest to follow the clinical outcome from the 
combination of systemic administration of TKI and local administration of these non-
invasive eye drops in GO patients. Future studies will more and more address the topic 
of combination treatment, based on the complex processes involved in the 
pathogenesis of fibrotic diseases and will potentially establish the most effective 
combinations for clinical use in GO. 
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English Summary          
 
*UDYHV¶ RSKWKDOPRSDWK\ *2 DOVR UHIHUUHG WR DV WK\URLG H\H GLVHDVH LV DQ H[WUD-
thyroidal complication that develops in ~25-RISDWLHQWVZLWK*UDYHV¶GLVHDVH*'
an autoimmune disease of the thyroid gland that results in hyperthyroidism). Clinical 
symptoms of GO result from the increase in orbital tissue volume within the non-
compliant space limited bony orbital cavity. These clinical symptoms comprise amongst 
others upper eyelid retraction, edema, erythema of the periorbital tissues and 
conjunctivae, and proptosis. The clinical course of GO consists of an initial active phase 
with inflammation and edema. This active phase may persist several months, then 
activity subsides and progresses to a chronic inactive phase with extensive orbital 
tissue remodeling and fibrosis. Immunologically active GO is characterized by infiltration 
of the extraocular muscles and adipose/connective tissue with mononuclear cells, 
primarily CD4+ T lymphocytes, some CD8+ T lymphocytes, monocytes, macrophages, 
B lymphocytes and plasma cells. Mast cells are more abundant in the chronic fibrotic 
disease phase. These inflammatory cells activate orbital fibroblasts via the secretion of 
inflammatory mediators (e.g. cytokines), autoantibodies (directed against thyrotropin 
receptor (TSH-receptor; TSHR) and insulin-like growth factor 1 receptor (IGF-1R) or by 
physical cellular interaction with the orbital fibroblasts. The activated orbital fibroblasts 
increase their proliferative activity, produce inflammatory mediators, differentiate into 
adipocytes and pro-fibrotic myofibroblasts and produce excess amounts of extracellular 
matrix (ECM) components, especially the hydrophilic glycosaminoglycan hyaluronan. 
Thereby, orbital fibroblasts fulfill central roles in orbital inflammation and tissue 
remodeling in GO. 
Previous studies showed elevated platelet-derived growth factor (PDGF)-BB levels in 
GO orbital tissue and demonstrated that PDGF-BB stimulates proliferation, production 
of hyaluronan, cytokines/chemokines and enhances TSHR expression by orbital 
fibroblasts. In this thesis the contribution of PDGF-BB to GO was further explored as 
well as the inhibition of PDGF signaling by clinically available tyrosine kinase inhibitors 
(TKI) that prevent PDGF receptor (PDGF-R) auto-phosphorylation.  
In chapter 4 PDGF-BB was demonstrated to enhance adipogenesis of orbital 
fibroblasts cultured in a proadipogenic environment. This suggests that in GO PDGF 
can contribute to orbital tissue expansion by stimulating adipogenesis. However, this 
might be hugely dependent on the local environment that orbital fibroblasts encounter 
as preliminary studies in this thesis revealed that transforming growth factor (TGF)-E1, 
which is also elevated in GO, may inhibit the pro-adipogenic effects of PDGF-BB. These 
data do however illustrate the need to examine the effects that combinations of stimuli, 
e.g. growth factors and cytokines, exert on orbital fibroblasts. Along this line, basic 
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fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) have 
been proposed to contribute to GO as increased levels were found in orbital tissue and 
serum from GO patients. However, so far the effects of bFGF and VEGF, either alone or 
in combination with other growth factors, on orbital fibroblasts have hardly or not been 
studied. In chapter 5 it was demonstrated that VEGF marginally stimulated hyaluronan 
production by orbital fibroblasts, while it did not affect proliferation and interleukin (IL)-6 
production. bFGF stimulated proliferation and hyaluronan production by orbital 
fibroblasts, but not IL-6 production. VEGF did not modify the effects induced by bFGF 
and/or PDGF-BB. In contrast, bFGF synergistically amplified the effects of PDGF-BB on 
IL-6 and hyaluronan production by orbital fibroblasts and additively enhanced PDGF-
BB-induced orbital fibroblast proliferation. These data suggest that bFGF may 
represent an important contributor to GO pathogenesis, especially in conjunction with 
PDGF-BB. Further studies in chapter 6 showed that PDGF-BB and bFGF prolonged 
the duration of PDGF-B mRNA induction in the orbital fibroblasts compared to 
stimulation with PDGF-BB or bFGF alone. Studies with a PDGF-BB neutralizing 
antibody suggested that the synergistic effects of PDGF-BB and bFGF on hyaluronan 
and IL-6 production are mediated by induction of autocrine PDGF-BB signaling.   
During the chronic phase of GO mast cells are abundantly present within the orbital 
tissue. However, the contribution of mast cells and their products to GO are generally 
unknown. In chapter 7 increased mast cell numbers were observed in orbital tissues 
from patients with GO and they are located closely to orbital fibroblasts and adipocytes. 
Furthermore, it was found that the mast cell mediator histamine stimulated the 
production of the nuclear factor kappa-B (NF-NB) controlled-cytokines IL-6, IL-8 and 
chemokine (C-C motif) ligand (CCL)-2 by orbital fibroblasts, while the cytokines CCL5, 
CCL7,  chemokine (C-X-C motif) ligand (CXCL)-10 and CXCL11 that are controlled by 
other transcription factors were not induced by histamine. This effect of histamine was 
found to be mediated by the histamine receptor subtype-1 (HRH1) which was the 
histamine receptor subtype most abundantly expressed by orbital fibroblasts. From 
these data it can be proposed that mast cell derived histamine is involved in regulating 
inflammation and monocyte recruitment in GO orbital tissue. Mast cell inhibition or 
interference with histamine or histamine receptor activity may thus represent therapeutic 
targets for GO treatment. Remarkably, mast cells have previously been identified as 
source of PDGF-BB in GO and preliminary studies performed in this thesis suggest that 
PDGF-BB stimulates orbital fibroblasts to produce stem cell factor (SCF), an important 
growth factor for mast cells. These data support existence of an intricate interplay 
between mast cells and orbital fibroblasts in GO.  
Collectively, the in vitro data generated in this thesis have refined our understanding of 
the pathogenesis of GO (Figure 1). This can be of importance for optimization and 
development of future therapies, as will be further discussed hereunder.    
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production of NF-NB controlled cytokines, while it does not affect hyaluronan 
production.      
 
The PDGF-Rs and FGF receptors (FGF-Rs) belong to the receptor tyrosine kinase 
(RTK) family and can be targeted with TKI that specifically inhibit the tyrosine kinase 
activity of these receptors and thus their activation. The studies performed in chapter 3 
illustrated that the TKI dasatinib effectively suppressed PDGF-BB-induced proliferation, 
hyaluronan, CCL2, IL-6 and IL-8 production by orbital fibroblasts at low concentrations. 
Moreover, dasatinib was found to exhibit stronger anti-inflammatory, anti-proliferative, 
and hyaluronan synthesis-suppressing effects than the TKI imatinib mesylate. 
Dasatinib also inhibited PDGF-BB enhanced adipogenic differentiation of orbital 
fibroblasts (Chapter 4) and was found to suppress mRNA expression of CCL2, IL6, 
IL8, hyaluronan synthase 2 (HAS2) and the fat predominant transcription factor 
peroxisome proliferator-activated receptor (PPAR)-Ȗ in whole orbital tissue from GO 
patients (Chapters 3 and 4). Together these data showed that dasatinib can interfere 
with pathways that are involved in the pathophysiology of GO and based on these 
findings the potential clinical implications of dasatinib in GO should be further studied.    
 
In chapter 9 of this thesis we described for the first time the treatment of a patient with 
therapy-refractory GO with dasatinib. This female patient suffered from severe and 
progressive GO (clinical activity score (CAS) 6/7), despite treatment with high doses of 
glucocorticoids. In whole orbital tissue cultures from this patient treatment with 
dasatinib resulted in reduction in cytokine (IL6, IL8, CCL2, TNFD and IL10), HAS1-3, 
adhesion molecule (intercellular adhesion molecule 1 (ICAM-1)), and growth factor 
(TGF-ȕ1 and PDGF-B) mRNA expression. Based on the in vitro data, patient was 
subsequently treated with dasatinib once daily 100 mg. After 6 weeks of treatment 
clinical improvement was found with a CAS of 4/7. Four months after start of dasatinib, 
the patient seemed to become resistant to the treatment resulting in sight-threatening 
GO. Interestingly, pretibial myxedema (also characterized by excessive hyaluronan 
accumulation) completely disappeared upon dasatinib treatment and did not relapse 
until now. Collectively, these data support the potential clinical implication of the TKI 
dasatinib in patients with very severe and/or sight-threatening GO, in which 
conventional therapies are ineffective. However, optimal implementation might require 
further studies as is also clear from the trial described in chapter 8. Patients with 
therapy-refractory systemic sclerosis (SSc), as a clinical model for fibrotic diseases, 
were treated with imatinib mesylate. Of the ten patients described in this study, only two 
showed a significant reduction in modified Rodnan skin score (mRSS). The patients 
that responded to treatment with the TKI imatinib mesylate were those with biochemical 
evidence of excessive collagen synthesis (high serum levels of the N-terminal 
propeptide of collagen type-III (PIIINP) and active disease as reflected by high B-cell-
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activating factor (BAFF) mRNA levels in monocytes. These data suggest that serum 
PIIINP levels and monocyte BAFF mRNA levels could potentially be used as 
biomarkers to identify those SSc patients that might be eligible for therapy with imatinib 
mesylate or other TKI. Further studies will have to reveal whether these or other 
biomarkers could also be used in determining therapeutic approaches in GO patients.  
 
Moreover, therapies with other TKI that simultaneously target multiple key molecules in 
the pathogenesis of GO should be further explored. In chapter 5  it was demonstrated 
that nintedanib, a TKI that targets PDGF-Rs, FGF-Rs and VEGF-Rs, was more 
effective in inhibiting the combined effects of PDGF-BB and bFGF on orbital fibroblast 
activation than dasatinib, that targets PDGF-Rs but not FGFRs. Nintedanib was 
previously found to be effective in the treatment of patients suffering from idiopathic 
pulmonary fibrosis and based on the growth factors involved it could be hypothesized 
that nintedanib is a drug with potential clinical implications in the treatment of GO.   
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Nederlandse samenvatting        
 
De ziekte van Graves is een auto-immuunaandoening van de schildklier die leidt tot 
hyperthyreoïdie. Graves orbitopathie (GO), ook wel oogziekte van Graves genoemd, is 
een complicatie van de ziekte van Graves die optreedt in 25 tot 50% van de patiënten. 
De symptomen van GO zijn het gevolg van volumetoename van het orbitale weefsel in 
de oogkas. De oogkas bestaat uit botweefsel, waardoor er bij volumetoename van 
orbitaal weefsel druk uitgeoefend wordt op de structuren in deze oogkas. Het oog kan 
daardoor alleen naar voren verplaatst worden, wat leidt tot proptosis (uitpuilende, wijd 
opengesperde ogen), het typische klinische beeld. De verdere klinische symptomen van 
GO bestaan uit teruggetrokken onder- en/of bovenoogleden, oedeem, roodheid van de 
periorbitale weefsels en conjunctiva.  
Het beloop van GO wordt initieel gekenmerkt door een actieve fase met 
ontstekingsactiviteit en ontwikkeling van oedeem. Deze actieve fase kan maanden 
duren, waarna de ontstekingsactiviteit zal afnemen en het beeld zich zal ontwikkelen 
richting een chronische inactieve fase, gekenmerkt door een verstoorde 
weefselstructuur. Immunologisch wordt de actieve fase van GO gekenmerkt door 
infiltratie van extra-oculair spierweefsel en het orbitale vet- en bindweefsel met 
mononucleaire cellen, voornamelijk CD4+ T lymfocyten, en in mindere mate CD8+ T 
lymfocyten, monocyten, macrofagen, B lymfocyten en plasmacellen. Mestcellen zijn 
vaker aanwezig in de chronische fase, waarin fibrosering (overmatige 
bindweefselproductie) van weefsel optreedt. De infiltrerende ontstekingscellen activeren 
orbitale fibroblasten door de uitscheiding van ontstekingsmediatoren (zoals cytokinen 
en groeifactoren), auto-antistoffen (o.a. gericht tegen de thyroid stimulating hormone 
receptor (TSHR) en insulin-like growth factor 1 receptor (IGF-1R)) of via direct cel-cel 
contact tussen ontstekingscellen en orbitale fibroblasten. 
Geactiveerde orbitale fibroblasten verhogen hun celdeling, produceren 
ontstekingsmediatoren, differentiëren tot adipocyten (vetcellen) en pro-fibrotische 
myofibroblasten en produceren grote hoeveelheden extracellulaire matrix componenten, 
voornamelijk het hydrofiele glycosaminoglycaan hyaluronan. Op basis van deze 
processen wordt aan de orbitale fibroblasten een centrale rol in het ontstekingproces en 
de weefselverandering in GO toegekend. 
Voorgaande studies hebben aangetoond dat platelet-derived growth factor (PDGF)-BB 
verhoogd tot expressie komt in oogweefsel in GO en dat PDGF-BB de celdeling, 
productie van hyaluronan en cytokinen/chemokinen stimuleert. Bovendien zorgt PDGF-
BB voor een verhoogde expressie van TSHR op orbitale fibroblasten. In de studies 
beschreven in dit proefschrift wordt de rol van PDGF-BB in de pathogenese van GO 
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pathogenese van GO is echter nog niet opgehelderd. In de studies beschreven in 
hoofdstuk 7 werden verhoogde aantallen mestcellen gevonden in orbitaal weefsel van 
patiënten met GO en deze mestcellen werden aangetroffen in de directe omgeving van 
orbitale fibroblasten en adipocyten. Bovendien werd aangetoond dat de mestcel 
mediator histamine de productie van de door de transcriptiefactor  nuclear factor kappa-
B (NF-NB) gecontroleerde cytokinen IL-6, IL-8 en chemokine (C-C motif) ligand (CCL)-2 
door orbitale fibroblasten stimuleerde. Histamine had daarentegen geen invloed op de 
productie van CCL5, CCL7, chemokine (C-X-C motif) ligand (CXCL)-10 en CXCL11 die 
onder controle staan van andere transcriptiefactoren dan NF-NB. De effecten van 
histamine bleken te worden gemedieerd via histamine receptor subtype-1 (HRH1), het 
histamine receptor subtype dat voornamelijk tot expressie kwam op orbitale 
fibroblasten.  
Deze data suggereren dat histamine afkomstig uit mestcellen betrokken is bij de 
regulatie van ontsteking en het aantrekken van monocyten in orbitaal weefsel in GO. 
Remming van mestcel activiteit of interferentie met histamine of de histamine receptor 
kan derhalve een mogelijke therapeutische benadering zijn in de behandeling van GO. 
Opvallend in dit kader is het gegeven dat mestcellen in GO tevens een bron kunnen zijn 
van PDGF-BB en preliminaire studies zoals beschreven in dit proefschrift toonden aan 
dat PDGF-BB de orbitale fibroblasten aanzet tot de productie van stem cell factor 
(SCF), een belangrijke groeifactor voor mestcellen. Deze data ondersteunen de 
hypothese dat er in GO een belangrijke rol is weggelegd voor de interactie tussen 
mestcellen en orbitale fibroblasten.  
 
Samenvattend hebben de in vitro data die werden verkregen door de studies uit dit 
proefschrift meer inzicht gegenereerd in de processen betrokken in de pathogenese van 
GO (zie figuur 1). Deze nieuwe inzichten kunnen van groot belang zijn voor ontwikkeling 
en verbetering van de behandeling van GO, zoals hieronder verder wordt besproken. 
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beïnvloedt (grijze lijn), mogelijk als gevolg van lage VEGF-receptor (VEGF-R) 
expressie in orbitale fibroblasten. Daarentegen is de VEGF-R expressie op monocyten, 
macrofagen en endotheelcellen hoog en VEGF kan daardoor een mogelijk effect 
hebben op deze cellen in GO (onderbroken lijnen). PDGF-BB en bFGF hebben een 
synergistisch effect op IL-6 en vooral hyaluronan productie door orbitale fibroblasten 
(gecombineerde pijl). Orbitale fibroblasten brengen de histamine receptor subtype-1 
(HRH1) tot expressie en via deze receptor stimuleert histamine de productie van door 
NF-NB gecontroleerde cytokinen, terwijl het de hyaluronan productie niet beïnvloedt.      
 
De PDGF-Rs en FGF receptoren (FGF-Rs) behoren tot de receptor tyrosine kinase 
(RTK) familie. Deze receptoren kunnen beïnvloed worden door tyrosine kinase 
remmers (TKI), welke de tyrosine kinase activiteit en daardoor de activatie van deze 
receptoren remmen. De studies beschreven in hoofdstuk 3 hebben aangetoond dat de 
TKI dasatinib in lage concentraties in staat is de PDGF-BB geïnduceerde proliferatie, 
hyaluronan, CCL2, IL-6 en IL-8 productie door orbitale fibroblasten te onderdrukken. 
Bovendien heeft dasatinib een sterker anti-inflammatoir en antiproliferatief effect 
alsmede een sterker onderdrukkend effect op de productie van hylarunon door orbitale 
fibroblasten dan de TKI imatinib mesylaat. 
Dasatinib remde eveneens de door PDGF-BB gestimuleerde adipogenese van orbitale 
fibroblasten (hoofdstuk 4) en onderdrukte de mRNA expressie van CCL2, IL6, IL8, 
hyaluronan synthase 2 (HAS2) en peroxisome proliferator-activated receptor (PPAR)-Ȗ 
(een transcriptiefactor betrokken in adipogenese) in totaal orbitaal weefsel van patiënten 
met GO (hoofdstukken 3 en 4).  
Deze data hebben geleerd dat dasatinib kan interfereren met diverse processen die 
een belangrijke rol spelen in de pathogenese van GO en op basis van deze 
bevindingen zullen de mogelijke therapeutische opties van dasatinib in GO verder 
onderzocht moeten worden. 
 
In hoofdstuk 9 van dit proefschrift wordt voor de eerste keer de behandeling van een 
patiënte met een therapieresistente GO met dasatinib beschreven. Deze vrouwelijke 
patiënt leed aan een ernstige en progressieve GO (klinische activiteit score (CAS) 6/7), 
ondanks behandeling met hoge dosering glucocorticoïden. In kweken van totaal 
orbitaal weefsel van deze patiënte resulteerde incubatie met dasatinib tot afname van 
cytokine (IL6, IL8, CCL2, TNFD en IL10), HAS1-3, adhesiemolecuul (intercellular 
adhesion molecule 1 (ICAM-1)), en groeifactor (TGF-ȕ1 and PDGF-B) mRNA 
expressie in het weefsel. Op basis van deze in vitro data werd patiënte vervolgens 
behandeld met dasatinib 1 dd 100 mg. Na 6 weken behandeling was er een duidelijke 
afname van GO (CAS 4/7). Vier maanden na starten van de behandeling trad er echter 
progressieve ziekteactiviteit op, hetgeen leidde tot acute chirurgische interventie, 
vanwege een visusbedreigende situatie. Het pretibiaal myxoedeem (eveneens 
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gekarakteriseerd door excessieve accumulatie van hyaluronan) wat eveneens 
verdween na 6 weken behandeling bleef opvallend genoeg afwezig tot op heden.  
De in vitro en in vivo data ondersteunen de hypothese dat de TKI dasatinib een 
potentiele nieuwe behandeling biedt voor patiënten met ernstige en/of 
visusbedreigende GO, waar de conventionele behandelingen falen. Aanvullende 
studies, alvorens TKI op groter schaal kunnen worden ingezet in GO, zijn nodig zoals 
ook blijkt uit de studie beschreven in hoofdstuk 8. 
Patiënten met therapieresistente systemische sclerose (SSc), als een klinisch model 
voor fibroserende aandoeningen, werden behandeld met imatinib mesylaat. Van de 10 
patiënten beschreven in de studie, werd in twee gevallen een significante verbetering 
van het huidbeeld gevonden als gemeten middels de µPRGLILHGRodnan skin score¶ 
(mRSS). 
De patiënten die gunstig reageerden op de behandeling waren de patiënten met 
biochemische aanwijzingen voor excessieve collageen synthese (hoge serumwaarden 
voor het N-terminal propeptide of collagen type-III (PIIINP) en actieve ziekte, gemeten 
aan de hand van hoge B-cell-activating factor (BAFF) mRNA levels in monocyten.  
Deze data suggereren dat serum PIIINP waarden en monocyt BAFF mRNA levels 
gebruikt zouden kunnen worden als biomarkers om de patiënten met SSc te selecteren 
die in aanmerking komen voor een behandeling met imatinib mesylaat of andere TKIs. 
Vervolgstudies zullen moeten uitwijzen of deze of andere biomarkers ook gebruikt 
kunnen worden in het effectief inzetten van (nieuwe) behandelstrategieën in GO. 
Anderzijds zal verder onderzocht moeten worden of behandelingen met andere TKIs, 
die tegelijkertijd meerdere processen beïnvloeden die van belang zijn in de 
pathogenese van GO, zinvol kunnen zijn. In hoofdstuk 5 werden studies beschreven 
die aantoonden dat nintedanib, een TKI die zowel de PDGF-Rs, FGF-Rs en VEGF-Rs 
remt, effectiever was in het remmen van de gecombineerde effecten van PDGF-BB en 
bFGF op orbitale fibroblast activatie in vergelijking met dasatinib, dat wel de PDGF-
Rs beïnvloedt maar niet de FGF-Rs. Nintedanib was in klinische studies effectief in de 
behandeling van idiopathische longfibrose en op basis van de bekende factoren die 
betrokken zijn in de pathogenese van GO kan verondersteld worden dat nintedanib in 
de toekomst een mogelijke therapeutische rol kan spelen in de behandeling van GO. 
 
 
 
 

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